

## RESUME

**Profile:** A consultant with 10 years of experience in providing independent expertise in laboratory medicine and molecular genetics to health care organizations and life science innovators. Leveraging 25 years of leadership and front-line operating experience in clinical laboratory medicine, medical research, and academia.

### **Current Position**

Senior Consultant & Founder, Pitangus Consulting Inc., Vancouver, B.C., Canada.

### **Selected Achievements**

#### ***Management Consulting***

From 2000 to present, operating a full-time consulting business providing objective, unbiased expertise to pharmaceutical and biotechnology companies and to public and private sector organizations delivering health care services.

#### ***Leadership, Strategy, Implementation and Operations***

Led the Department of Laboratory Medicine at Sunnybrook Hospital from 1995 to 2002 and headed a multi-institutional cancer diagnostic program at the University of Toronto from 1986 to 1995.

As a Director of the Sunnybrook Hospital-Dynacare Laboratories joint venture (SDL) from 1995 to 2000, played a leadership and operational role in key strategic planning, budgetary and implementation processes.

In the 1980s developed and implemented the strategic plan for a regional clinical laboratory service and lobbied government, hospital and university sectors to fund the program's growth for over 20 years.

#### ***Administration, Finance and Business Analysis***

Provided financial analysis and strategic guidance to a team of health care administrator's responsible for a \$300M provincial annual budget for outpatient laboratory services.

With a management team, responsible to Sunnybrook Hospital for the financial accounting of laboratory medicine services delivered by a joint public/private venture (~\$32M/yr).

At Sunnybrook Hospital responsible for the clinical, academic and business activities of 15 physicians and 4 scientists.

Responsible for major clinical diagnostic activities at University of Toronto teaching Hospitals.

Chaired numerous multi-stakeholder search committees including department and division heads.

Prepared and reviewed several business opportunities for life sciences companies including StemCell Technologies Inc., in Vancouver.

#### ***Entrepreneurial, Community and Philanthropic Activities***

As president and founder of a private Canadian charity, raised a substantial endowment and invested it to provide on-going full-tuition undergraduate educational awards (20 awards to date). ([www.macvillefoundation.com](http://www.macvillefoundation.com))

Raised over \$14M (2011\$) to support research at University of Toronto teaching hospitals. Participated in several private sector initiatives including founding a Toronto real estate holding company.

# Ian Dubé

BSc, MSc, PhD, MBA

As one of seven voting Councillors of Runnymede Public School in Toronto, worked to advance pupil achievement and to make the public school system more accountable to parents.

## **Academic, Research and Awards**

Directed peer-review funded medical research at the University of Toronto for 17 consecutive years.

Published over 100 scientific articles and 14 book chapters. Edited one book. Made over 90 invited research presentations (several international).

Received the 1993 Junior Scientist Award of the Canadian Association of Pathologists for the cloning and characterization of a new gene involved in human leukemia.

Received the 1996 Distinguished Service Award, Department of Pathology, University of Toronto.

Promoted to full professor rank in the Faculty of Medicine at the University of Toronto in 1999.

## **Government Service**

Consultant clinical analyst to multiple Canadian Provincial Ministries of Health, 2002 to present.

With the Toronto Biotechnology Initiative, organized a National symposium on a new technology in 1995.

With Health Canada, chaired an OECD-sponsored 1995 workshop on an emerging biotechnology.

Appointed by Ontario provincial government Order in Council as a regional chairman for genetic services, played a key role in development of the region's annual budget proposal.

Scientific Officer, Canadian Institutes for Health Research (University-Industry grant panel, 2004-2008).

## **Education**

B.Sc. (1977) University of B.C.;

M.Sc. (1980) UBC (Medical Genetics);

Ph.D. (1984) UBC (Medical Genetics);

Diploma in Health Administration (2001) University of Toronto, Program in Health Administration;

M.B.A. (2002) Queen's University School of Business (Executive MBA);

Other: Executive development courses including Harvard Law School's Program in Negotiation (2001).

## **Recent Projects**

Clinical analytical support to a team of health care administrators negotiating a \$300M+ contract for the provision of provincial laboratory services.

Recommendations to the executive of a Toronto Stock Exchange-listed biotechnology company on the development of a business plan for a newly licensed technology.

Development of a plan to address the delivery of population-based genetic testing services for the senior leadership team of a major health care provider.

Independent assessment of a business case for a regional cancer screening program.

Development of a ministry of health's position on publicly funded vitamin D testing.

**I. BIOGRAPHICAL INFORMATION**

- A) Full Name : Ian David Dubé  
B) Date CV Prepared : November 2011  
C) City Location : Vancouver, B.C.  
E) Email : [info@iandube.com](mailto:info@iandube.com)  
F) Citizenship : Canadian  
G) Year of Birth : 1956

**II. EDUCATION**

B.Sc.	1977	University of B.C. (First Class Honours, Zoology.)
M.Sc.	1980	University of B.C. (Medical Genetics.)
Ph.D.	1984	University of B.C. (Medical Genetics.)
Dip. H.A.	2001	Univ. of Toronto, Program in Health Administration.
M.B.A.	2002	Queen's University School of Business (Executive MBA).

**III. EMPLOYMENT**

**A. Present**

Principal and Founder, Pitangus Consulting Inc., Vancouver, B.C.

**B. Past Appointments**

**Academic**

Professor, Faculty of Medicine, Department of Laboratory Medicine and Pathobiology, University of Toronto, 1999 - 2004.

Continuing Member, School of Graduate Studies, University of Toronto, 1986 - 2004.

**Hospital**

Head, Department of Laboratory Medicine, Sunnybrook Campus, Sunnybrook & Women's College Health Sciences Centre, 1995-2002

Senior Staff Scientist, Sunnybrook and Women's College Health Sciences Centre Research Institute, 1995 - 2004.

Active Medical Staff, Department of Clinical Pathology, Sunnybrook Campus, Sunnybrook & Women's College Health Sciences Centre, 2000 -2004.

**Private Sector**

Business Development Consultant, Special Projects, StemCell Technologies, Vancouver, B.C., 2004-2006.

Consultant Scientific Advisor, MedBiogene, Vancouver, B.C., 2006-2007.

**C. Cross Appointments**

School of Graduate Studies, University of Toronto, 1989 - 2004.

Institute of Medical Sciences, University of Toronto, 1991 - 2004.

Department of Medicine, University of Toronto, 1995 - 2004.

**D Relevant Experience**

- Consultant clinical analyst, BC's Ministry of Health Services, Medical Services Division, 2006 – present.
- Clinical Fellow, Division of Cytogenetics, Department of Genetics, The Hospital For Sick Children, Toronto, 1984-1986.
- Director, University of Toronto Teaching Hospitals' Cancer Cytogenetics and Molecular Oncology Program, 1986-1995.
- Consultant Medical Staff (Scientist), Department of Pediatrics, Division of Hematology/ Oncology, The Hospital For Sick Children, 1986-1996.
- Medical-Dental Staff (Scientist), Department of Laboratory Hematology, Sunnybrook Health Science Centre, Toronto, 1986-1995.
- Medical Staff (Scientist), Department of Pathology, Toronto General Hospital 1986-1996.
- Head, Division of Cytogenetics, Department of Pathology, Toronto General Hospital 1986-1989.
- Consultant Medical Staff, Department of Pathology, The Princess Margaret Hospital, Toronto, 1986 -1991.
- Consultant Medical Staff, Department of Pathology (Hematology), The Wellesley Hospital, Toronto, 1986 -1992.
- Consultant Medical Staff, Department of Pathology, Toronto Western Division, The Toronto Hospital, 1989-1995.
- Acting Director, Clinical Cytogenetics Division, Department of Pathology, The Toronto Hospital, 1994-1995.
- Scientific Director, The Toronto Hospital's Gene Therapy Program in Hematology/ Oncology, 1994-1996.
- Head, Department of Laboratory Medicine, Sunnybrook Health Science Centre, Toronto, 1995-1998.
- Active Medical Staff, Department of Clinical Pathology, Sunnybrook Campus, Sunnybrook & Women's College Health Sciences Centre, 2000 -2004.

**E. Research Experience**

- Graduate Studies leading to M.Sc. (Medical Genetics): 1977 -1980.
- Graduate Studies leading to Ph.D. (Medical Genetics): 1980 -1984.
- Research Fellow, Department of Genetics and Division of Hematology/ Oncology, The Hospital For Sick Children, Toronto: 1984 -1986.
- Staff Scientist, Department of Pathology, The Toronto Hospital, Toronto: 1984 - 1996.
- Senior Staff Scientist, The Toronto Hospital Research Institute, Toronto: 1994 - 1996.
- Scientific Director, The Toronto Hospital's Gene Therapy Program in Hematology- Oncology, 1994 -1995.
- Staff Scientist, Oncology Research Program, The Toronto Hospital, 1994-1997.
- Senior Staff Scientist, Research Institute, Sunnybrook Health Science Centre, Toronto: 1995 - 2002.

**IV. HONOURS/ AWARDS**

- A.** K. M. Hunter Award, (National Cancer Institute): 1981.  
National Cancer Institute Studentship, Terry Fox Special Award: 1982.  
National Cancer Institute Studentship, Terry Fox Special Award: 1983.  
Terry Fox Training Centre Fellowship, National Cancer Institute and The Hospital For Sick Children, Toronto, 1984-1986.  
Linda Stevens Memorial Travel Fund Award: 1985.  
Dean's Fund Award, Faculty of Medicine, University of Toronto: 1986.  
The Scientific Award, Canadian Association of Pathologist: 1993.  
Distinguished Service Award, Department of Pathology, University of Toronto, 1996.

**B. Awards to Students:**

1. Dick Wells: Best Presentation Given by a Hematology Resident; Annual Meeting of the Royal College of Physicians and Surgeons of Canada, Vancouver, B.C., 1993. Title of presentation: *Molecular genetics of acute promyelocytic leukemia.*
2. Carolyn Lutzko: Farber Award for Best Oral Presentation (M.Sc.), Dept. of Cellular & Molecular Pathology, University of Toronto, 1994. Title of presentation: *Canine model for gene therapy of MPS1.*
3. Monika Hudoba: First Prize Winner at the Third Annual Pathology Residents Research Day, University of Toronto, 1996. Title of presentation: *Pre-clinical studies of gene therapy for Gaucher Disease.*
4. Monika Hudoba: Ontario Association of Pathologists Award for Best Presentation made by a Resident at the Annual Meeting. Toronto, Ontario, 1996. Title of presentation: *Pre-clinical studies of gene therapy for Gaucher Disease.*
5. Carolyn Lutzko: The American Society of Hematology Annual Meeting Travel Award. Orlando, Florida, 1996. Title of presentation: *Gene therapy for an enzyme deficiency state is abrogated by immune responses to gene modified hematopoietic stem cells.*
6. Carolyn Lutzko: The Canadian Hematology Society Award for Excellent Presentation at the CHS Trainee Presentation Session, Royal College of Physicians & Surgeons of Canada Annual Meeting, Toronto, Ontario, September, 1998. Title of presentation: *Genetically corrected autologous stem cells, but host immune responses limit their utility in canine  $\alpha$ -L-iduronidase deficiency.*
7. Tarja Juopperi: Parke Davis Award for the Best MSc Oral Presentation at the Annual Graduate Student Research Day; Department of Laboratory Medicine & Pathobiology; Toronto, Ontario; March, 2000. Title of presentation: *Retroviral-mediated gene transfer expression of the multidrug resistance protein 1 (MRP1) for hematopoietic chemoprotection.*

**V. PROFESSIONAL AFFILIATIONS/ACTIVITIES**

**A) International**

- American Society of Hematology: Member, 1989 - 2005.  
American Society of Human Genetics: Member, 1979 - 2000.

American Society for Cancer Research: Member, 1990 - 2000.  
International Society for Experimental Hematology: Member, 1996 - 2000.  
International Society of Hematotherapy and Graft Engineering: Member, 1996 - 2000.  
American Society of Gene Therapy, Member, 1997 - 2000.  
The 10th International Human Gene Mapping Workshop, Workshop on Neoplasia: Member, 1989-1990.  
National Institute for Health (USA): External Grant Referee, 1990-1994, 1998.  
The Ottawa/July 1995 Workshop on Gene Delivery Systems for Human Gene Therapy, sponsored by The Organization for Economic Cooperation and Development and the National Health Departments of 25 western countries: Scientific Chairman, 1994-1995.  
The Rome Workshop on Model Systems for the Study of Human Pathologies and Basic Biological Research, Sponsored by the Organization for Economic Cooperation and Development and the British Health Department: Canadian Representative, Task Force Planning 1996-1997.  
American Society of Hematology Annual Meeting. New Approaches to Gene Therapy Simultaneous Session: Session Moderator, 1996.  
Program Committee of the Pharmaceutical Aspects of Biotechnology and Gene Therapy Products- International Open Conference on Regulations, Standards, and Harmonization. Sponsored by USP and FIP. Supported by FDA-CBER, FDA-CDER, DD-Canada, IBAC, AAPS: Member, 1997-1998.  
Canadian Council of The American Society for Gene Therapy: Elected Member, 1997-2000.  
Comitato Promotore, Italian Foundation for Research on Muscular Dystrophy and other Genetic Diseases: Member, Scientific Review Panel, 1997-1999.  
Scientific Committee on Hematopoietic Cell Gene therapy, American Society of Gene Therapy: Member, 1997-1999.  
The American Society for Human Genetics Annual Meeting, Cancer Genetics II Simultaneous Session: Session Moderator, 1998.  
The 28<sup>th</sup> International Society of Hematology World Congress: Member-Organizing Committee, Canadian Scientific Advisory Board, 2000.  
Referee for: American Journal of Pathology(1993,1996) Blood (1987,1991,1993,1994-2002) Bone Marrow Transplantation(1996) Cancer Research(1993,1995) Experimental Hematology(1998-2002) Genes, Chromosomes and Cancer (1989-1996) Human Gene Therapy(1996,1998-2001) Journal of Cutaneous Medicine and Surgery(1996) Journal of the Royal College of Pathologists of Australasia(1988-1989) Proceedings of the National Academy of Science (USA) (1991-1993).

**B) National**

Canadian Institutes for Health Research: External Grant Referee (1990 - 2002); Scientific Officer, University-Industry grant review panel (2004 – 2008).  
The Genetics Society of Canada: Member, 1978-1988.  
National Cancer Institute of Canada, Grant Review Panel; (Hemopoiesis and Pathology): Member, 1986-89.

National Cancer Institute of Canada: External Grant Referee (1988-2002).  
British Columbia Health Care Research Foundation: External Referee (1990-1995, 1998-1999, 2000).  
The Hospital for Sick Children Research Foundation: External Referee (1991-1993, and 1995).  
The Canadian Red Cross Society Research and Development Fund: External Referee (1992-1994).  
Chairman, The Canadian scientific delegation to the London (UK) Task Force on Planning the Ottawa/July 1995 OECD Workshop on Gene Delivery Systems for Human Gene Therapy; 1994.  
The Canadian Association of Pathologists: Associate Member, 1994-2000.  
The Molecular Pathology Section of the Canadian Association of Pathologists: Member, 1995-2000.  
Bayer/Canadian Red Cross Society Research and Development Fund. External Referee (1995, 1997, and 1998).  
The Molecular Pathology Section of the Canadian Association of Pathologists: Member, 1995-1999.  
Scientific Chair of the June 26<sup>th</sup> and 27<sup>th</sup>, 1995, Toronto, *Gene Therapy in Canada* Symposium sponsored by the Canadian Institute for Biotechnology and the Toronto Biotechnology Initiative.  
The Gairdner Foundation: Member, Medical Review Panel; 1996-1999.  
The Canadian Hematology Association: Member, 1996-2000.  
Muscular Dystrophy Association of Canada. External Grant Referee, 1996.  
National Cancer Institute of Canada, Grant Review Panel H (Hematopoiesis and signal transduction): Scientific Officer, 1996-1998.  
Alberta Heritage Foundation for Medical Research: External Referee, 1997.  
Scientific Co-Chair, *Gene Therapy in Canada Symposium 2*, June 2 and 3, 1997 Vancouver, B.C.  
Organizer and Chairman of the Symposium: *Hematologic Diagnosis- Tools for the Future*; The Canadian Hematology Association's Program for the 1999 Meeting of the Royal College of Physicians and Surgeons of Canada; September 24<sup>th</sup>, 1999.

**C) Provincial**

Toronto Institute of Medical Technology: Advisory Committee for Continuing Courses in Cytogenetics: Member, 1984-1986.  
Ontario Central East Regional Sub-Committee of the Ontario Provincial Advisory Committee on Genetic Services: Chairman, 1988-1991, Secretary, 1986 - 1988.  
Ontario Provincial Advisory Committee on Genetic Services: Member, 1988 - 1991.  
Ad Hoc Subcommittee of the Provincial Genetics Advisory Committee on Cancer Genetics and Cytogenetics: Chairman, 1988-1991.  
Committee on Cancer Cytogenetics and Molecular Genetics of the Joint Liaison Committee of the OCI/OCTRF: Chairman, 1991-1995.  
The Toronto Biotechnology Initiative: Member, 1992-2004.

Sunnybrook-Dynacare Laboratories, Board of Directors, Member 1995-1999.  
Molecular Pathology Advisory Committee. Ontario Medical Association,  
Laboratory Proficiency Testing Program: Corresponding Member, 1996-  
1999.

**D) University**

University of Toronto Department of Pathology, Assistant Professor, 1986-1992.  
Ad Hoc Committee of the Oncology Coordinating Council on Special Clinical  
Laboratory Services in Oncology, University of Toronto: Member, 1987.  
University of Toronto Program in Genetic Medicine Committee: Member 1991 -  
1993.  
Graduate Program Appeals Committee, Department of Pathology, University of  
Toronto: Member, 1991-1994.  
University of Toronto Department of Pathology, Associate Professor, 1992-1997.  
Graduate Student Admissions Committee, Department of Community Health  
(MHSc Part-time Program) University of Toronto: Member, 1992.  
Diagnostic Services Committee, Department of Pathology, University of Toronto;  
Chairman of Sub-committee on Cytogenetics: 1992 - 1993.  
Departmental Finance Committee, Department of Pathology: Member, 1992 -  
1999.  
Departmental Research Committee, Department of Pathology: Member 1992 -  
1994.  
University of Toronto, Dean's Clinical Biochemistry and Pathology Merger  
Committee (The Pinkerton Committee): Member, 1994.  
University of Toronto, Department of Pathology, Search Committee for  
Chairman: Member, 1994.  
Gairdner Award Nominations Sub-Committee (Ron Worton-Chair; Janet  
Rowley- Nominee): Member, 1995.  
Oncology Session Chair, 1995 Annual Meeting of the Clinical Research Society  
of Toronto.  
University of Toronto, Dean's Clinical Biochemistry, Medical Microbiology and  
Pathology Merger Committee (The Langer Committee): Member, 1995  
Oncology Session Chair, 1996 Annual Meeting of the Clinical Research Society  
of Toronto.  
Genetics Session Chair, 1996 Annual Meeting of the Clinical Research Society  
of Toronto.  
Sub-committee on Service of the Steering Committee on Consolidation of  
Clinical Biochemistry/Medical Microbiology/ Pathology: Member, 1996  
University of Toronto Department of Laboratory Medicine and Pathobiology,  
Associate Professor, 1997-1999.  
University of Toronto, Department of Laboratory Medicine and Pathobiology,  
Professor, 1999 - 2004.

**E) Hospital**

Search Committee for Director of Clinical Cytogenetics, Toronto General  
Hospital: Chairman, 1986-87.  
Toronto Chorion Villus Sampling Trial Committee: Member, 1986-1988.

Executive Committee, Department of Pathology, Toronto General Hospital: Member, 1986-1988, 1991-1993.  
Toronto Antenatal Genetics Clinic Executive Committee: Member, 1986-1988, 1994-1995.  
Search Committee for Clinical Geneticist, Toronto General Hospital: Member, 1987- 1992.  
Toronto General Hospital Genetic Services Coordinating Committee of the Medical Advisory Board: Member 1989 -1992.  
Search Committee for Associate Director and Director of Molecular Diagnostics, University of Toronto Hospitals' Cancer Cytogenetics Program: Chairman, 1990.  
Search Committee for The Hospital For Sick Children Laboratory Scientist in Molecular Pathology: Member, 1991-1992.  
Search Committee for Head, Division of Anatomical Pathology, Sunnybrook Health Science Centre: Committee Chair, 1995-1996.  
Executive Committee, Integrative Biomedical Sciences, Sunnybrook Health Science Centre, Member 1995- 1998.  
Senior Medical Council, Sunnybrook Health Science Centre: Member, 1995-1999.  
Advanced Therapeutic Program, Sunnybrook Health Science Centre: Member of the Executive Committee, 1995-1999.  
Medical Advisory Committee, Sunnybrook Health Science Centre: Member, 1995-1999.  
Academic Medical Council, Sunnybrook Health Science Centre: Member, 1995-1999.  
Sunnybrook-Dynacare Laboratories, Board of Directors: Member 1995-2000  
Senior Medical Council, Sunnybrook & Women's College Health Sciences Centre: Member, 1998-1999.  
Executive Committee, Integrative Biomedical Sciences, Sunnybrook & Women's College Health Sciences Centre: Member 1998-1999.  
Advanced Therapeutic Program, Sunnybrook & Women's College Health Sciences Centre: Member of the Executive Committee, 1998-1999.  
Academic Medical Council, Sunnybrook & Women's College Health Sciences Centre: Member, 1998-1999.  
Medical Advisory Committee, Sunnybrook Campus, Sunnybrook & Women's College Health Sciences Centre: Member, 1998-1999.

## VI. ACADEMIC HISTORY

### A. Research Endeavours

Gene Therapy  
Genetic Basis of Cancer.  
Biology of Blood in Health and Cancer

B. Research Awards (Total for 1986 - 2004 = \$14,167,912 in 2011\$)

Medical Research Council of Canada - Canadian Institutes of Health Research

- 1987 \$ 1,300 Supervisor's Grant (Ron Carter)  
1988 \$ 1,300 Supervisor's Grant (Ron Carter)  
1989 \$ 1,300 Supervisor's Grant (Ron Carter)  
1994 \$ 3,500 Supervisor's Grant (David Allan)  
1995 \$ 3,500 Supervisor's Grant (David Allan)  
1995 \$ 2,500 Symposium Grant (Gene Therapy in Canada)  
1996 \$ 3,600 PMAC/MRC Studentship Grant (Tara Paton)  
1988 \$56,000/yr 2 Years Operating Grant (Principal investigator with co-investigators VEO Valli and S Kruth). Title: *Canine model for autologous bone marrow transplantation using long-term bone marrow culture cells.*  
1989 \$57,000/yr 3 Years Operating Grant (Principal investigator). Title: *Cloning and characterization of the oncogene involved in the 10;14 translocation of T-cell neoplasia.*  
1990 \$75,100/yr 3 Years Operating Grant (Principal investigator with co-investigators VEO Valli and S Kruth). Title: *Canine model for autologous bone marrow transplantation using long-term bone marrow culture cells.*  
1993 \$30,000/yr 1 Year Operating Grant (Principal investigator with co-investigators S. Kamel-Reid, S. Kruth, and ACG Abrams-Ogg). Title: *Gene transfer into pluripotent hematopoietic progenitor cells.*  
1994 \$94,000/yr 3 Years Operating Grant (Principal investigator with co-investigators S. Kamel-Reid, S. Kruth, and ACG Abrams-Ogg). Title: *Gene transfer into pluripotent hematopoietic progenitor cells.*  
1997 \$45,528 Operating Grant (Principal investigator with co-investigators A.K. Stewart, S. Kruth, and ACG Abrams-Ogg). Title: *Gene transfer into pluripotent hematopoietic progenitor cells.*  
1998 \$97,653/yr. 4 years Operating Grant (Principal investigator with co-investigators S. Kruth and ACG Abrams - Ogg). Title: *Gene therapy in a model system: Canine alpha-iduronidase deficiency.*  
2002 \$129,372/yr. 1 year Operating Grant (Co-principal investigator with S. Kruth and M. Hough). Title: *Gene therapy in a model system: Canine alpha-iduronidase deficiency.*  
2004 \$172,583/yr 3 years (Co author with M. Hough, principal investigator and co-investigator S. Kruth). Title: *Efficacy and safety of lentiviral vector-mediated gene therapy in a large animal model.* (Note: Successful independent project renewal).

Stem Cell Network Center of Excellence

- 2001 \$132,000 3 years (I. Dubé's portion) Operating grant. (Co-investigator with R.C. Worton and 34 Canadian scientists). *Therapeutics approaches with hematopoietic stem cells.*

2002 \$10,000/yr 2 years. Graduate Studentship Award- Ali Rouhani. *Hematopoietic stem cell gene therapy in a large animal pre-clinical model: canine mucopolysaccharidosis type 1.*

**National Cancer Institute of Canada**

- 1992 \$121,694/yr 3 Years Operating Grant (Principal investigator with S. Kamel-Reid). Title: *Characterization of HOX11: A new gene involved in human cancer.*
- 1997 \$156,413/yr 3 Years Operating Grant (Co-investigator with A.K. Stewart, principal investigator and coinvestigators A. Abrams-Ogg and S. Kruth) Title: *MDR-1 transduced autologous marrow cells for chemoprotection in metastatic breast cancer.*
- 1999 \$110,639/yr 3 Years Operating Grant. (Principal investigator with M. Hough) Title: *Pathogenesis of tumor progression in a transgenic mouse model for lymphoma.*
- 2002 \$133,405/yr 3 Years Operating Grant (Co-investigator with M. Hough, principal investigator) Title: *Pathogenesis of tumor progression in a transgenic mouse model for lymphoma.*

**Bayer Blood Partnership Fund**

- 1998 \$75,400/yr 2 years Operating Grant. (Principal investigator). Title: *Molecular genetic characterization of the inductive hematopoietic microenvironment.*
- 2000 \$112,400/yr. 1.5 year (Renewal). (Principal investigator). Title: *Molecular genetic characterization of the inductive hematopoietic microenvironment.*

**University of Toronto**

- 1986 \$ 5,000 Dean's Fund Award.
- 1987 \$30,000 Faculty of Medicine, Excellence Award.

**Toronto General Hospital**

- 1986 \$13,000 Oncology Research, Start-up Fund

**The Hospital For Sick Children Foundation**

- 1988 \$50,000/yr 2 Years Operating Grant (Principal investigator). Title: *Molecular characterization of the (10;14) translocation of childhood T-cell acute lymphoblastic leukemia.*
- 1990 \$48,000/yr 2 Years Operating Grant (Principal investigator). Title: *Molecular characterization of breakpoints in complex Philadelphia chromosomes.*
- 1994 \$55,000/yr 2 Years Operating Grant (Principal investigator). Title: *Gene therapy for human ADA-deficiency.*

**Canadian Universities Research Program - Connaught Laboratories Ltd.**

1994 \$120,000/yr 3 Years Operating Grant (Principal investigator) . Title: *A mouse model for human gene therapy.*

**The Banting Medical Research Foundation**

1988 \$10,000 Equipment Grant. Title: *Cloning and characterization of the oncogene involved in the 10;14 translocation of T-cell neoplasia.*

**Somatix Therapy Corp.**

1995 \$57,876 Research Contract (Principal investigator). Title: *Transduction of hematopoietic stem cells with the MFG virus carrying the human glucocerebrosidase gene.*

**Genetic Therapy Inc.**

1996 \$ 83,808 Research Contract (Principal Investigator) Title: *Transfer of the MDR gene into hematopoietic stem cells.*

**The Canadian Society for Mucopolysaccharide and Related Diseases Inc.**

1996 \$5,000 (Principal investigator with S. Kruth co-investigator). Title: *Support for a canine MPS 1 colony.*

**Other Corporate Research Awards**

1995 \$27,350 Funding for Gene Therapy in Canada Conference. Donors include: Inex, Hemosol, Biochem, Glaxo, Genentech, Novopharm, Coopers & Lybrand, MDS Health Group, Allelix, Dalton, General Synthesis & Diagnostics Inc., Bayer, Scott & Ayles, Cansera, Eli Lilly, Toronto Biotechnology Initiative, Connaught, Imutec, Spectral Diagnostics Inc., Canadian Institute of Biotechnology, Medical Research Council.

**C. Patents**

- 1993 Method and Product of Gene Transfer into Cells. U.S. Patent Application No. 08/003,300, and Canadian Application No.2,096,844-9. (Rights assigned to: University of Toronto Innovations Foundation.)
- 1998 HOX11 Transgenic Mice. U.S. Patent Application No.60/077,007. (Rights assigned to: Sunnybrook & Women's College Health Sciences Centre.)
- 2000 Growth Factors Genes. Canadian Patent Application #2,299,607 and U.S. Patent Application No. 60/193,358. (Rights assigned to: Sunnybrook & Women's College Health Sciences Centre.)

VII. **SCHOLARLY WORK AND CREATIVE PROFESSIONAL ACTIVITIES**

A. **Theses**

- B.Sc. (Honors) The Incidence of Sister Chromatid Exchanges in Cultured Human Lymphocytes. University of British Columbia, 1977.
- M.Sc. Cytogenetic Analysis of Single Hemopoietic Colonies. University of British Columbia, 1980. (C. J. Eaves, Supervisor).
- Ph.D. In Vitro Cytogenetic Studies in Chronic Myeloid Leukemia, University of British Columbia, 1984. (C. J. Eaves, Supervisor).

B. **Clinical Trials**

1. A phase 1 study of autologous bone marrow transplantation with stem cell gene marking in multiple myeloma. AK Stewart, ID Dubé, S Kamel-Reid, A Keating. March 1st, 1994.
2. A phase 1 study of adenovirus mediated gene transfer of interleukin2 cDNA into metastatic breast cancer and melanoma. AK Stewart, N. Lassani, J Gauldie, F Graham, M Krajden, M Crump, ID Dubé, R Foley, P Goss, S Karp, I Quirt. June 1st 1995.
3. A phase I/II trial of MDR-1 chemoprotection in metastatic breast cancer. AK Stewart, ID Dubé, RM Crump, A Bank. April 1st, 1996.
4. A phase 1 study of autologous gene modified plasma cell vaccination following peripheral blood stem cell transplantation for the control of minimal residual myeloma. AK Stewart, J Meharchand, ID Dubé, FL Graham, J. Gauldie, RG Hawley. March 1st, 1997.

C. **Publications (Journal Articles)**

1. Dubé ID, Eaves CJ, Kalousek DK, Eaves AC. A method of obtaining high quality chromosome preparations from single hemopoietic colonies on a routine basis. *Cancer Genetics and Cytogenetics* 1981;4;157-168.
2. Dubé ID, Gupta CM, Kalousek DK, Eaves CJ, Eaves AC. Cytogenetic studies of early myeloid progenitor compartments in Ph1-positive chronic myeloid leukemia (CML). Persistence of Ph1-negative committed progenitors that are suppressed from differentiating in-vivo. *British Journal of Haematology* 1984;56:633-644.
3. Coulombel L, Eaves CJ, Dube ID, Kalousek DK, Eaves AC. Variable persistence of leukemic progenitor cells in long-term CML and AML marrow cultures. *Kroc Foundation Series*. 1984;18: 243-54.
4. Dubé ID, Kalousek DK, Coulombel L, Gupta CM, Eaves CJ, Eaves AC. Cytogenetic studies of early myeloid progenitor compartments in Ph1-positive chronic myeloid leukemia (CML). II. Long-term culture reveals the persistence of Ph1-negative progenitors in treated as well as newly diagnosed patients. *Blood* 1984;63:1172-1177.
5. Dubé ID, Arlin ZA, Kalousek DK, Eaves CJ, Eaves AC. Non-clonal hemopoietic progenitor cells detected in long-marrow cultures from a Turner syndrome

- mosaic with chronic myeloid leukemia (CML). [Concise Report] *Blood* 1984;64:1284-1287.
6. Eaves C, Coulombel L, Dubé I, Kalousek D, Cashman J, Eaves A. Behavior of human leukemic progenitor populations in long-term marrow culture. *Hematologie Und Bluttransfusion*. 1985;29: 163-7.
  7. Eaves C, Coulombel L, Dubé I, Kalousek D, Cashman J, Eaves A. Maintenance of normal and abnormal hemopoietic cell populations in long-term cultures of CML and AML marrow cells. *Progress in Clinical and Biological Research*. 1985;184: 403-13.
  8. Dubé ID, El Solh H. An apparent tandem quadruplication of chromosome 21 in a case of childhood acute lymphoblastic leukemia (ALL). *Cancer Genetics and Cytogenetics* 1986;23:253-256.
  9. Dubé ID, Greenberg ML. Phenotypic heterogeneity in three cases of lymphoid malignancy with chromosomal translocations in 14q11. *Cytogenetics and Cell Genetics* 1986;41:215-218.
  10. Dubé ID, Raimondi SC, Pi D, Kalousek DK. A new translocation, t(10;14)(q24;q11), in T-cell neoplasia. [Concise Report] *Blood* 1986;67:1181-1184.
  11. Estrov Z, Grunberger T, Dubé ID, Wang YP, Freedman MH. Detection of residual acute lymphoblastic leukemia cells in cultures of bone marrow obtained during remission. *New England Journal of Medicine* 1986;315:538-542.
  12. Estrov Z, Tawa A, Wang YP, Dubé ID, Solh H, Cohen A, Gelfand EW, Freedman M. In vitro and in vivo effects of desferoxamine in neonatal acute leukemia. *Blood* 1987;69:757-761.
  13. Estrov Z, Dubé ID, Chan H, Freedman M. Residual juvenile chronic myelogenous leukemia cells detected in peripheral blood during clinical remission. *Blood* 1987;70:1466-1469.
  14. Worton RG, Sutherland J, Sylvester JE, Williard HF, Bodrug S, Dubé ID, Duff C, Kean V, Ray PN, Schmickel RD. Human ribosomal RNA genes: Orientation of the tandem array and conservation of the 5' end. *Science* 1988;239:64-68.
  15. Kalousek DK, Dubé ID, Eaves CJ, Eaves AC. Cytogenetic studies of hemopoietic colonies from patients with an initial diagnosis of acute lymphoblastic leukemia. *British Journal of Haematology* 1988;70:5-11.
  16. Raimondi SC, Dubé ID, Valentine MB, Mirrow J Jr, Watt HJ, Larsen RA, Le Beau MM, Rowley JD. Clinico-pathologic manifestations and breakpoints of the t(3;5) in patients with acute non-lymphocytic leukemia. *Leukemia* 1988;3:42-47.
  17. Narod SA, Dubé ID. Occupational history and involvement of chromosomes #5 and #7 in acute non-lymphocytic leukemia. *Cancer Genetics and Cytogenetics* 1989;38:261-269.
  18. Battaglia D, Dubé ID, Pinkerton P, Senn, J. Acquisition of additional primary chromosome abnormalities in the course of karyotype evolution in a case of FAB-M2 acute leukemia. *Cancer Genetics and Cytogenetics* 1989;40:105-110.
  19. Dubé ID, Dixon J, Beckett T, Grossman A, Weinstein M, Benn P, McKeithan T, Norman C, Pinkerton P. Location of breakpoints within the major breakpoint cluster region (bcr) in 33 patients with bcr-rearrangement positive chronic

- myeloid leukemia (CML) with complex or absent Philadelphia chromosomes. *Genes, Chromosomes and Cancer* 1989;1:106-111.
20. Korneluk RG, MacKenzie AE, Nakamura Y, Dubé ID, Jacob P, Hunter AGW. A reordering of human chromosome 19 long-arm DNA markers and identification of markers flanking the myotonic dystrophy locus. *Genomics* 1989;5:596-604.
  21. Stewart K, Carstairs KC, Dubé ID, Keating A. Neutrophilic myelofibrosis presenting as Philadelphia chromosome negative BCR non-rearranged chronic myeloid leukemia. *American Journal of Hematology* 1989;34:59-63.
  22. Colwill R, Dubé ID, Scott JG, Bailey D, DeHarven E, Carstairs KC, Pantalony D. Isochromosome 7q as the sole abnormality in an unusual case of T-lineage malignancy. *Hematologic Pathology* 1989;4(1):53-58.
  23. Al-Jaouni S, Pinkerton PH, Sheridan BL, Dubé ID, Norman C. Breakpoints involved in deletions of the long arm of chromosome 5 in myelodysplasia and acute non-lymphoblastic leukemia do not correlate with the morphological diagnosis. *Leukemia and Lymphoma* 1990;3:195-200.
  24. Schuh AC, Sutherland DR, Horsfall W, Mills GB, Dubé ID, Baker MA, Siminovitch S, Bailey D, Keating A. Chronic myeloid leukemia arising in a progenitor common to T cells and myeloid cells. *Leukemia* 1990;4:631-636.
  25. Lu M, Dubé ID, Raimondi S, Carroll A, Minden M, Sutherland P. Molecular characterization of the t(10;14) translocation breakpoints in T-cell acute lymphoblastic leukemia: Further evidence for illegitimate physiological recombination. *Genes, Chromosomes & Cancer* 1990;2:217-222.
  26. Carter RF, Kruth SA, Valli VEO, Dubé ID. Long-term culture of canine marrow: Cytogenetic evaluation of purging of lymphoma and leukemia. *Experimental Hematology* 1990;18:995-1001.
  27. Pinkerton PH, London B, Dubé ID, Senn JS. Trisomy 14q in myelodysplastic syndromes. *Cancer Genetics and Cytogenetics* 1990;49:113-116.
  28. Dubé ID, Carter RF, Pinkerton PH. Chromosome abnormalities in chronic myeloid leukemia: A model for acquired chromosome changes in haematological malignancy. *Tumor Biology* 1990;1(Suppl 1):3-24.
  29. Carter RF, Dubé ID, McKeithan T, Bailey D, DeHarven E, Carstairs K, Scott JG. Translocation (14;19) in acute biphenotypic leukemia. *Cancer Genetics and Cytogenetics* 1991;53:67-73.
  30. Reis MR, Dubé ID, Pinkerton PH, Chen-Lai J, Robinson JB, Klock RJ, Senn JS. Jumping translocations involving band 3q13.3 in a case of acute monocytic leukemia. *Cancer Genetics and Cytogenetics* 1991;51:189-194.
  31. Kapelushnik J, Dubé ID, Wilson P, Greenberg M. Acute lymphoblastic leukemia with 4;11 translocation following osteogenic sarcoma. *Cancer* 1991;67:2887-2889.
  32. Lishner M, Amato D, Chalvardjian P, Baker M, Fernandes B, Pantalony D, Dubé ID. Unusual findings in two patients with acquired deletions of the long-arm of chromosome 5 (5q-). *Clinical and Laboratory Haematology* 1991;13:87-92.
  33. Lewis MES, Solh H, Dubé ID. Secondary acute non-lymphocytic leukemia (ANLL) with monosomy 7 arising 9 years after acute lymphoblastic leukemia (ALL) in childhood. *Cancer Genetics and Cytogenetics* 1991;55:85-88.

34. LeBrun DP, Pinkerton PH, Sheridan BL, Chen-Lai J, Dubé ID, Poldre PA. Essential thrombocythemia with the Philadelphia chromosome and BCR-ABL gene rearrangement -An entity distinct from chronic myeloid leukemia and Philadelphia chromosome negative essential thrombocythemia. Cancer Genetics and Cytogenetics 1991;54:21-25.
35. Reis MD, Dubé ID. Gene rearrangement studies in the assessment of lymphoid neoplasias. Invited editorial. Leukemia and Lymphoma 1991;4:313-316.
36. Pinkerton PH, Dubé ID. Chronic myeloid leukemia as a paradigm for oncogenesis. Diagnostic Oncology 1991;1:288-297.
37. Cohen A, Grunberger T, Vanek W, Dubé ID, Doherty PJ, Letarte M, Roifman C, Freedman MH. Constitutive expression and role in growth regulation of interleukin-1 and multiple cytokine receptors in a biphenotypic leukemic cell line. Blood 1991;78:94-102.
38. Dubé ID, Kamel-Reid S, Yuan CC, Lu M, Wu X, Corpus G, Crist W, Carroll AJ, Baker J. A novel human homeobox gene lies at the chromosome 10 breakpoint in lymphoid neoplasias with chromosomal translocation t(10;14). Blood, 1991;78:2996-3003.
39. Carter RF, Abrams-Ogg ACG, Dick JE, Kruth SA, Valli VE, Kamel-Reid S, Dubé ID. Autologous transplantation of canine long-term marrow culture cells genetically marked by retroviral vectors. Blood, 1992;79(2):356-364.
40. Lorber BJ, Freeman S, Hassold T, Ragab A, Cockwell AE, Jacobs PA, Radford M, Doyle J, Dubé ID, Zipursky A. Characterization and molecular analysis of non-disjunction in 18 cases of trisomy 21 and leukemia. Genes, Chromosomes & Cancer 1992;4:222-227.
41. Borrow J, Goddard AD, Gibbons B, Katz F, Swirsky D, Dubé I, Winfield DA, Hagemeijer A, Rees JKH, Young B, Solomon E. Diagnosis of acute promyelocytic leukemia by RT-PCR: Detection of PML-RARA and RARA-PML fusion transcripts. British Journal of Haematology, 1992;82:529-540.
42. DeCoteau JF, Dubé ID, Kamel-Reid S. Recent advances in the detection of minimal residual malignant hematological disease. Diagnostic Oncology, 1992;2:168-173.
43. Reis MD, Sher GD, Lakhani A, Dubé ID, Senn JS, Pinkerton PH. Deletion of the long arm of chromosome 5 in essential thrombocythemia. Cancer Genetics and Cytogenetics, 1992;61:93-95.
44. Brandwein J, Dubé ID, Layara P, Keating A. Maintenance of Philadelphia-chromosome positive progenitors in long-term marrow cultures from patients with advanced chronic myeloid leukemia. Leukemia, 1992;6(6)556-561.
45. Abrams-Ogg AC, Kruth SA, Carter RF, Valli VE, Kamel-Reid S, Dubé ID. The use of an implantable central venous (Hickman) catheter for long-term venous access in dogs undergoing bone marrow transplantation. Canadian Journal of Veterinary Research, 1992;56(4),382-386
46. Pinkerton PH, Reis MD, DeCoteau JF, Srigley JR, Dubé ID, London B. A lineage-specific translocation, t(1;14)(q21;q32) as an early event in the development of a B-cell clonal expansion. Cancer Genetics and Cytogenetics, 1992;64:166-169.

47. Abrams-Ogg ACG, Kruth SA, Carter RF, Valli VE, Kamel-Reid S, Dubé ID. Preparation and transfusion of canine platelet concentrates. *American Journal of Veterinary Research*, 1993;54(4):635-642.
48. Abrams-Ogg ACG, Kruth SA, Carter RF, Dick JE, Valli VE, Kamel-Reid S, Dubé ID. Clinical and pathologic findings in dogs following supralethal total body irradiation with and without infusion of autologous long-term marrow culture cells. *Canadian Journal of Veterinary Research*, 1993;57:79-88.
49. Sanchez-Sweatman OH, de Harven EP, Dubé ID. Human Chromosomes: Evaluation of processing techniques for scanning electron microscopy. *Scanning Microscopy*, 1993;7:97-106.
50. Freedman M, Grunberger T, Correa P, Axelrad AA, Dubé ID, Cohen A. Autocrine and paracrine growth-control by GM-CSF of acute lymphoblastic leukemia cells. *Blood*, 1993;81:3068-3075.
51. Raju K, Tang S, Dubé ID, Kamel-Reid S, Bryce DM, Breitman ML. Characterization and developmental expression of *Tlx-1*, the murine homolog of *HOX11*. *Mechanisms of Development*, 1993;44:51-64.
52. Bienzle D, Abrams-Ogg ACG, Kruth S, Ackland-Snow J, Dick J, Jacobs R, Kamel-Reid S, Dubé ID. Gene transfer into hematopoietic stem cells: Long-term maintenance of *in vitro* activated progenitors without marrow ablation. *Proceedings of the National Academy of Sciences USA*, 1994;91:350-354.
53. Schnurr MW, Carter RF, Dubé ID, Valli VE, Jacobs RM. Nonrandom chromosomal abnormalities in bovine lymphoma. *Leukemia Research*, 1994;18(2):91-99.
54. Lau RC, Squire J, Brisson L, Kamel-Reid S, Grunberger T, Dubé ID, Letarte M, Shannon K, Freedman MH. Lymphoid blast crisis of B-lineage phenotype with monosomy 7 in a patient with juvenile chronic myelogenous leukemia (JCML). *Leukemia*, 1994;8(5):903-908.
55. Choi BCK, de Harven E, Bailey DJ, Dubé ID, Pantalony D. Cell type identification in leukemia: The level of agreement among four independent diagnostic methods. *Cancer Detection and Prevention*, 1994;18(5):383-391.
56. Hudoba M, Dubé ID. Molecular and cytogenetic abnormalities in childhood acute lymphoblastic leukemia and their impact on outcome. *Diagnostic Oncology*, 1994; 4: 344-352.
57. Lichty B, Ackland-Snow J, Noble L, Kamel-Reid S, Dubé ID. Dysregulation of *HOX11* by chromosome translocation in T-ALL: A paradigm for homeobox gene involvement in human cancer. *Leukemia and Lymphoma*, 1995;16:209-215.
58. Stewart AK, Dubé ID, Kamel-Reid S, Keating A. A phase I study of autologous bone marrow transplantation with stem cell gene marking in multiple myeloma. *Human Gene Therapy*, 1995;6:107-119.
59. Dubé ID, Cournoyer D. Gene therapy: Here to stay. *Canadian Medical Association Journal*, 1995;152:1605-1613.
60. Dubé ID, Stewart K, Lutzko C, Kruth S, Abrams-Ogg A, Shull R, Kohn D, Reddy V, Chu P, Kamel-Reid S. Gene transfer into marrow-derived hematopoietic stem cells. *Gene Therapy*, 1995;2:579-580.
61. Stewart AK, Dubé ID. Monitoring cancer relapse with retroviral gene marked autologous blood or bone marrow cells. *Gene Therapy*, 1995;2:590-591.

62. Dubé ID, Stewart AK. Adoptive transfer of genetically modified hematopoietic stem cells. *Transfusion Science*, 1996; 17:1,137-145.
63. Borrow J, Shearman AM, Stanton VP, Reinhard B, Collins T, Williams AJ, Dubé ID, Katz F, Kwong YL, Morris C, Ohyashiki K, Toyama K, Rowley J, Housman DE. The t(7;11)(p15;p15) translocation in acute myeloid leukemia fuses the genes for nucleoporin *NUP98* to class I homeoprotein *HOXA9*. *Nature Genetics*, 1996;12:159-167.
64. Stewart AK, Prince HM, Dubé ID. Background and update to a phase I trial of stem cell gene marking in multiple myeloma. *Transfusion Science*, 1996;17:1, 175-184.
65. Wells RA, Hummel, JL, DeKoven A, Zipursky A, Kirby M, Dubé ID, Kamel-Reid S. A new variant translocation in acute promyelocytic leukemia: molecular characterization and clinical correlation. *Leukemia*, 1996;10. 735-740.
66. Lutzko C, Chu P, Dubé ID. Gene transfer into hematopoietic stem cells. *Transfusion Science*, 1996 17:1, 129-136.
67. Borrow J, Stanton V, Andresen JM, Reinhard B, Behm FG, Chaganti RSK, Civin CI, Disteché C, Dubé ID, Frischau AM, Horsman D, Mitelman F, Watmore AE, Housman DE. The t(8;16)(p11;p13) translocation of acute myeloid leukemia fuses the CREB-binding protein to a zinc finger protein homologous to the yeast silencing protein SAS2. *Nature Genetics*, 1996;14. 33-41.
68. Dubé ID. Guest editorial: Gene therapy in Canada. *Transfusion Science*, 1996;17:1,3-5.
69. Hummel J, Lichty B, Reis M, Dubé ID, Kamel-Reid S. Engraftment of human chronic lymphocytic leukemia cells in SCID mice; *in vivo* and *in vitro* studies. *Leukemia*, 1996;10, 1370-1376.
70. Dubé ID, Kruth S, Abrams-Ogg A, Kamel-Reid S, Lutzko C, Nanji S, Ruedy C, Singaraja R., Wild A, Krygsman P, Chu P, Messner H, Reddy V, McGarrity G, Stewart AK. Pre-clinical assessment of human hematopoietic progenitor cell transduction in long-term marrow cultures. *Human Gene Therapy*, 1996;7,2089-2100.
71. Allan DS, Dubé ID. Symposium Highlights: Future Prospects for Gene Therapy. *Transfusion Science*, 1996; 17:1, 203-205.
72. Allan DS, De Koven A, Wild A, Kamel-Reid S, Dubé ID. Endogenous murine leukemia virus DNA sequences in murine cell lines: Implications for gene therapy safety testing by PCR. *Leukemia and Lymphoma*, 1996;23, 375-381.
73. Shull R, Lu X, Dubé ID, Lutzko C, Kruth S, Abrams-Ogg A, Kiem H-P, Goehle S, Schuening F, Milan C, Carter R. Humoral immune response limits gene therapy in canine MPS-1. *Blood*, 1996, 88;377-379.
74. Allan D, Dubé ID. Retroviral-mediated gene transfer into long-term cultures of human bone marrow: Progress towards human gene therapy. *Health Sciences Journal*, 1997; 1:1, 46-52.
75. Stewart AK, Prince HM, Chu P, Lutzko C, Sutherland DR, Dubé ID. In vitro maintenance and transduction of human myeloma cells in long-term marrow cultures. *Cancer Gene Therapy*, 1997; 4:3;148-156.

76. Perkins D, Brennan S, Carstairs K, Bailey D, Pantalony D, Poon A, Fernandez B, Dubé ID. Regional cancer cytogenetics: a report on 1,143 diagnostic cases. *Cancer Genetics and Cytogenetics*, 1997; 96:64-80.
77. Stewart AK, Lassam N, Gauldie J, Graham F, Kraiden M, Crump M, Dubé ID, Foley R, Goss P, Karp S, Quirt I. A phase 1 study of adenovirus mediated gene transfer of interleukin 2cDNA into metastatic breast cancer or melanoma. *Human Gene Therapy*, 1997; 8:1403-1414.
78. McKeithan TW, Takimoto GS, Ohno H, Byorling V, Hecht BK, Dubé ID, Sandberg AA, Rowley JD. *BCL3* rearrangements in t(14;19) chronic lymphocytic leukemia and other B-cell malignancies: a molecular and cytogenetic study. *Genes Chromosomes & Cancer*, 1997;20:1;64-72.
79. Stewart AK, Schimmer AD, Bailey DJ, Dubé ID, Cappe D, Moen RC, Gauldie J, Graham FL. *In vivo* adenoviral-mediated gene transfer of interleukin-2 in cutaneous plasmacytoma. *Blood*, 1998; 91(3);1095-1097.
80. Chu P, Lutzko C, Stewart AK, Dubé ID. Retrovirus-mediated gene transfer into hematopoietic stem cells. *Journal of Molecular Medicine*, 1998; 76(3/4):184.192.
81. Imrie K, Dubé ID, Prince HM, Girouard C, Crump M, Keating A. New clonal karyotypic abnormalities acquired following autologous bone marrow transplantation for acute myeloid leukemia do not appear to confer an adverse prognosis. *Bone Marrow Transplantation*, 1998; 21:395-399.
82. Catzavelos C, Ruedy C, Stewart AK, Dubé ID. A novel method for the direct quantification of gene transfer into cells using PCR *in situ*. *Gene Therapy*, 1998; 5:755-760.
83. Tisdale JF, Stewart AK, Dickstein B, Dubé ID, Cappe D, Dunbar CE, Brown KE. Molecular and serological examination of the relationship of human herpesvirus 8 to multiple myeloma: orf 26 sequences in bone marrow stroma are not restricted to myeloma patients and other regions of the genome are not detected. *Blood*, 1998; 92:8; 2681-2687.
84. Hough MR, Reis MD, Singaraja R, Bryce DM, Kamel-Reid S, Dardick I, Breitman ML, Dubé ID. A model for spontaneous B-lineage lymphomas in IgH $\mu$ -HOX11 transgenic mice. *Proceedings of the National Academy of Sciences (USA)*, 1998; 95:13853-13858.
85. Omori F, Lutzko C, Abrams-Ogg A, Lau K, Gartley C, Dobson H, Nanji S, Ruedy C, Reis M, Robinson J, Pinkerton P, Stewart AK, Kruth S, Dubé ID. Adoptive transfer of genetically modified human hematopoietic stem cells into pre-immune canine fetuses. *Experimental Hematology*, 1999; 27: 242-249.
86. Lutzko C, Kruth S, Abrams-Ogg ACG, Lau K., Liheng L, Clark BR, Ruedy C, Nanji S, Foster R, Kohn D, Shull R, Dubé ID. Genetically corrected autologous stem cells engraft, but host immune responses limit their utility in canine  $\alpha$ -L-iduronidase deficiency. *Blood*, 1999; 93(6):1895-1905.
87. Hummel JL, Wells RA, Dubé ID, Licht J, Kamel-Reid S. Deregulation of NPM and PLZF in a variant t(5;17) case of acute promyelocytic leukemia. *Oncogene*, 1999;18:633-641.
88. Lutzko C, Dubé ID, Stewart AK. Recent progress in gene transfer into hematopoietic stem cells. *Critical Review in Oncology/Hematology*, 1999; 30:143-158.

89. Lutzko C, Omori F, Abrams-Ogg ACG, Shull RM, Liheng L, Lau K, Ruedy C, Nanji S, Gartley C, Dobson H, Foster R, Kruth S, Dubé ID. Gene therapy for canine  $\alpha$ -L-iduronidase ( $\alpha$ -ID) deficiency: *In utero* adoptive transfer of genetically corrected hematopoietic progenitors results in engraftment but not amelioration of disease. *Human Gene Therapy*, 1999;10(9):1521-1532.
90. Stewart AK, Sutherland DR, Nanji S, Zhao Y, Lutzko C, Nayar R, Peck B, Ruedy C, McGarrity G, Tisdale J, Dubé ID. Engraftment of gene-marked hematopoietic progenitors in myeloma patients after transplant of autologous long-term marrow cocultures. *Human Gene Therapy*, 1999; 10:1953-1964.
91. Omori F, Juopperi T, Chan CK, Chang YN, Phipps S, Nanji S, Zhao Y, Stewart AK, Dubé ID. Retroviral-mediated transfer and expression of the multidrug resistance protein (MRP) gene protects human hematopoietic cells from antineoplastic drugs. *Journal of Hematotherapy & Stem Cell Research*, 1999; 8:503-514.
92. Buckstein R, Imrie K, Spaner D, Potichnyj A, Robinson JB, Nanji S, Pennel N, Reis MD, Pinkerton PH, Dubé ID, Hewitt K, Berinstein NL. Stem cell function and engraftment is not effected by “*in vivo* purging” with Rituxan for autologous stem cell treatment for patients with low grade non-Hodgkin’s lymphoma. *Seminars in Oncology*, 1999;26(5 Suppl 14):115-122.
93. Lutzko C, Abrams-Ogg ACG, Li L, Zhao Y, Lau K, Kruth S, Dubé ID. Fractionation of gene modified hematopoietic autografts into multiple weekly infusions does not improve engraftment in unconditioned canine recipients. *Hematology*, 2000;4:499-503.
94. Shahnavaz SA, Regezi JA, Bradley G, Dubé ID, Jordan RCK. p53 gene mutations in sequential oral epithelial dysplasias and squamous cell carcinomas. *Journal of Pathology*, 2000;190(4):417-422.
95. Rosic-Kablar S, Chan K, Reis MD, Dubé ID, Hough MR. Induction of tolerance to immunogenic tumor antigens associated with lymphomagenesis in HOX11 transgenic mice. *Proceedings of the National Academy of Science, USA*, 2000;97(24):13300-13305.
96. Lutzko C, Meertens L, Li L, Abrams-Ogg A, Woods P, Kruth S, Hough MR, Dubé ID. Human hematopoietic progenitors engraft in fetal canine recipients and expand with neo-natal injection of fibroblasts expressing human hematopoietic cytokines. *Experimental Hematology*, 2002; 30:801-808.
97. Meertens L, Li L, Rosic-Kablar S, Chan K, Dobson H, Gartley C, Lutzko C, Hopwood J, Kohn D, Kruth S, Hough M, Dubé I. In utero injection of  $\alpha$ -L-iduronidase containing retrovirus in canine MPSI: Infection of multiple tissues and neo-natal gene expression. *Human Gene Therapy*, 2002;13:1809-1820.
98. Elenitoba-Johnson, KSJ, Jenson, SD, Abbott, RT, Palais RA, Bohling, SD, Lin Z, Tripp S, Shami PJ, Wang LY, Coupland RW, Buckstein R, Perez-Ordenez B, Perkins SL, Dubé ID, Lim, MS. Involvement of multiple signaling pathways in follicular lymphoma transformation: p38MAP kinase as a central target for therapy. *Proceedings of the National Academy of Science, USA*, 2003;100(12): 7259-7264.

99. Zhao Y, Chen E, Li L, Gong B, Xie W, Nanji S, Dubé ID, Hough MR. Gene expression profiling in the inductive human hematopoietic environment. *Biochem Biophys Res Commun*. 2004;323(2):703-711.
100. Chen E, Lim M, Rosic-Kablar S, Liu J, Jolicoeur J, Dubé ID. Dysregulated expression of mitotic regulators is associated with B-cell lymphomagenesis in HOX11-transgenic mice. *Oncogene*, 2006;25(18):2575-2587.
101. Chen E, Kwon YT, Lim MS, Dubé ID, Hough MR. Loss of Ubr1 promotes aneuploidy and accelerates B-cell lymphomagenesis in TLX1/HOX11-transgenic mice. *Oncogene*, 2006;25(42):5752-5763.
102. Dubé ID. Dad's mooring buoy – Cockpit confessions. *Pacific Yachting*, (2010) (January):122.

**D. Non-Refereed Publications (Abstracts)**

1. Dubé ID, Eaves AC, Eaves CJ. A new technique for the cytogenetic analysis of cells from single hemopoietic colonies of bone marrow or peripheral blood origin. [Abstract] *American Journal of Human Genetics*, 1980;32:68A.
2. Dubé ID, Kalousek DK, Gupta CM, Eaves CJ, Eaves AC. Cytogenetic analysis of single hemopoietic colonies in leukemia can reveal different cell populations from those identified in direct preparations. [Abstract] *American Journal of Human Genetics*, 1981;33:62A.
3. Gupta CM, Coulombel L, Eaves AC, Eaves CJ, Dubé ID, Kalousek DK. Unexpected proliferation of Ph1-negative cells in CML marrow cultures under conditions that favour myelopoiesis. [Abstract] *American Journal of Human Genetics*, 1982;34:70A.
4. Kalousek DK, Dubé ID, Eaves CJ, Eaves AC. Cytogenetic analysis of myeloid progenitors in Ph1-positive ALL. [Abstract] *Journal of Cellular Biochemistry*, 1983;53(suppl):7B.
5. Eaves AC, Dubé ID, Gupta CM, Eaves CJ, Kalousek DK. Persistence of functional Ph1-negative stem cells in a patient with established Ph1-positive CML using long-term marrow culture. [Abstract] *Experimental Hematology*, 1983;82 (suppl):14.
6. Dubé ID, Gupta CM, Kalousek DK, Eaves CJ, Eaves AC. Chromosomally normal myeloid progenitors in Philadelphia-Positive CML. [Abstract] *American Journal of Human Genetics*, 1983;35:62A.
7. Dubé ID, Kalousek DK, Eaves CJ, Eaves AC. Variation in Ph1-positive progenitor maintenance in long-term CML marrow cultures. [Abstract] *Journal of Cellular Biochemistry*, 1984;85 (suppl):8A.
8. Dubé ID, Arlin ZA, Kalousek DK, Eaves CJ, Eaves AC. Non-clonal hemopoietic progenitor cells detected in long-term marrow cultures from a Turner syndrome mosaic with chronic myeloid leukemia (CML). [Abstract] *American Journal of Human Genetics*, 1984;36 (suppl):28S.
9. Dubé ID, Weitzman S, Poon AO, Greenberg ML. Deletion in the short arm of chromosome 9 in a case of childhood acute lymphoblastic leukemia without

- lymphomatous features. [Abstract] In: Canadian Congress of Biology Program and Abstract Book, 1985;GS9.
10. Dubé ID, Greenberg ML. Heterogeneity among lymphoid malignancies bearing translocations in the chromosomal region 14q11-13. [Abstract] Blood, 1985(66)(suppl 1):235A.
  11. Estrov Z, Grunberger T, Dubé ID, Freedman MH. Detection of residual acute lymphoblastic leukemia cells in cultures of remission marrows. [Abstract] Proceedings of ASCO, 1986;5:152.
  12. Dubé ID, Raimondi SC, Kalousek DK. A new non-random translocation in T-cell neoplasia suggests that chromosomal band 10q24 may be the site of a putative oncogene. [Abstract] Proceedings of the 7th International Congress of Human Genetics, Springer-Verlag, Berlin, 1986.
  13. Dubé ID, Teshima IE, Swansbury GJ, Keating A, Baker MA, Doyle JJ. Patients with vitamin B12 deficiency express chromosomal fragile sites and have an elevated breakage frequency. [Abstract] American Journal of Human Genetics, 1986;39 (suppl) A111.
  14. Worton RG, Sutherland J, Bodrug S, Dubé ID, Duff C, Kean V, Schmickel RD, Sylvester J, Williard HF, Ray PN. Orientation of ribosomal RNA genes and isolation of acrocentric specific probe ACR-1 mapping distal to the ribosomal RNA genes. [Abstract] Cytogenetics and Cell Genetics, 1987;46:720.
  15. Schuh A, Horsfall W, Sutherland DR, Toneguzzo F, Mills GB, Dubé ID, Baker MA, Saragosa R, Keating A. CML in T-cell blast crisis may arise in a progenitor common to T-cells and myeloid cells. [Abstract] Blood, 1987;70(5)(suppl 1):209A.
  16. Dubé ID, Lu M, Minden MD, Raimondi SC, Sutherland PS, Beckett TA. Breakpoints occur within the delta-chain locus of the T-cell receptor gene in the t(10;14)(q24;q11) of T-cell neoplasia. [Abstract] American Journal of Human Genetics, 1988;43 (3):A23.
  17. Pinkerton PH, Chen Lai J, Robinson JB, Reis MD, Senn JS, Dubé ID. Jumping translocation involving chromosome band 3q13.3 in a case of acute non-lymphocytic leukemia (FAB M5). A rare cytogenetic pattern. [Abstract] Blood, 1988;72(5)(Suppl 1):220A.
  18. Dubé ID, Dixon J, Beckett T, Minden M, Norman C, Pinkerton P. Breakpoints in the bcr in complex Philadelphia chromosomes (Ph1's) are different from those in standard Ph1's. [Abstract] Blood, 1988;72(5)(Suppl 1):177A.
  19. Dubé ID, Lu M, Minden M, Raimondi S, Willard H, Carroll A. Cloning of the breakpoint in the 10;14 translocation of T-cell neoplasia and identification of a chromosome 10 specific sequence. [Abstract] Journal of Cellular Biochemistry, 1989; Suppl. 13B:83:E110.
  20. Brandwein JM, Laraya P, Dubé ID, Keating A. Studies of long-term marrow culture in patients with acute and chronic myeloid leukemia. [Abstract] Experimental Hematology, 1989;17:587.
  21. MacKenzie AE, Nakamura Y, Dubé ID, Korneluk RG. A seven locus chromosome 19 linkage group encompassing the myotonic dystrophy locus. [Abstract] Cytogenetics and Cell Genetics, 1989;51:1036.

22. Dubé ID, Lu M, Raimondi SC, Carroll A, Cohen A. Cloning of the TCL3 oncogene. [Abstract] *Cytogenetics and Cell Genetics*, 1989;51:993.
23. Lu M, Dubé ID, Raimondi, S, Carroll A. Sequencing of the breakpoint in the t(10;14) of T-cell neoplasia and identification of the putative TCL3 oncogene mRNA. [Abstract] *American Journal of Human Genetics*, 1989;45:(4)A27.
24. Dubé ID Dixon J, Beckett T, Benn P, McKeithan T. Location of breakpoints within the major breakpoint cluster region (bcr) in 33 patients with bcr rearrangement-positive chronic myeloid leukemia (CML) with complex or absent Philadelphia chromosomes. [Abstract] *American Journal of Human Genetics*, 1989;45:(4)A19.
25. Carter RF, Ogg A, Kruth SA, Valli VE, Dick JE, Dubé ID. Canine model for autologous bone marrow transplantation (AuBMT) using long-term culture (LTMC) cells. *Blood*, 1989;74(7)(Suppl 1)26a.
26. Carter RF, Dubé ID, Valli VE, Kruth SA. Canine model for autologous marrow transplantation (ABMT) using long-term marrow culture (LTMC) cells. [Abstract] *Cancer Genetics and Cytogenetics*, 1989;41:256.
27. Chang H, Wang X-H, Yee C, Dubé ID, Minden MD, Messner HA. A human lymphoma cell line with multiple immunoglobulin rearrangements. [Abstract] *Blood*, 1989;74(7)(Suppl 1)26a.
28. Carter RF, Ogg A, Kruth SA, Valli VE, Dick J, Bosch B, Dubé ID. Canine model for autologous marrow transplantation (AuBMT) with long-term culture (LTMC) cells. [Abstract] *Journal of Cellular Biochemistry*, 1990; Suppl 14A:326;C504
29. Carter RF, Ogg ACG, Kruth SA, Dick JE, Valli VE, Dubé ID. High-efficiency gene transfer into canine stem cells by repeated retroviral infection of long-term cultured autologous marrow transplants. [Abstract] *American Journal of Human Genetics*, 1990;47:3 (Suppl) A211.
30. Lorber BJ, Freeman S, Ragab A, Doyle J, Dubé ID, Zipursky A, Jacobs PA, Cockwell A, Hassold T. Analysis of non-disjunction in leukemic Down syndrome individuals. [Abstract] *American Journal Human Genetics*, 1990;47:3(Suppl)A33.
31. Stewart AK, Brandwein J, Dubé ID, Layara P, Keating A. Long term marrow culture (LTMC) of cytogenetically-abnormal acute myeloid leukemia (AML). [Abstract] *Blood*, 1990;76(10)(Suppl 1)324a.
32. Brandwein JM, Dubé ID, Layara P, Keating A. Long term marrow cultures (LTMC) in chronic myeloid leukemia (CML); the influence of interferon therapy. [Abstract] *Blood*, 1990;76(10)(Suppl 1)256a.
33. Carter RF, Abrams-Ogg ACG, Kruth SA, Valli VE, Dick JE, Dubé ID. Genetic marking of canine stem cells: Autologous transplantation of retrovirally infected long-term marrow culture cells. [Abstract] *Blood*, 1990;76(10)(Suppl 1)531a.
34. Dubé ID, Lu M, Raimondi S, Carroll A, Wu X, Baker J, Hogg D. The TCL3 oncogene is expressed in normal tissue and is dysregulated via recombinase mediated recombination in leukemic cells from patients with t(10;14) T-ALL. [Abstract] *Blood*, 1990;76 (10) (Suppl 1)230a.
35. Abrams-Ogg ACG, Kruth SA, Carter RF, Valli Veo, Dubé ID, Dick JE. Autologous bone marrow transplantation using long-term bone marrow culture in

- dogs. [Abstract] *American Journal of Veterinary Internal Medicine*, 1990;4(2):100.
36. Dubé ID, Kamel-Reid S, Yuan CC, Wu X, Corpus G, Crist W, Carroll A, Baker J. HOX11, a new homeobox gene, is deregulated in lymphoid neoplasias with the t(10;14)(q24;q11) translocation. [Abstract] *American Journal of Human Genetics*, 1991;49(4)Suppl 1)45.
37. Abrams-Ogg ACG, Kruth SA, Lewis CJ, Carter RF Dubé ID. Preparation of canine platelet concentrates. [Abstract] *Journal of the American College of Veterinary Internal Medicine*, 1991;5p149.
38. Abrams-Ogg ACG, Kruth SA, Carter RF, Valli Veo, Dubé ID, Dick JE. Autologous bone marrow transplantation and retrovirally mediated gene transfer in dogs. [Abstract] *Journal of the American College of Veterinary Internal Medicine*, 1991;5:p138.
39. Dubé ID, Kamel-Reid S, Yuan C, Lu M, Wu X, Corpus G, Raimondi S, Crist W, Carroll A, Baker J. HOXII; a new homeobox gene deregulated in lymphoid neoplasias with chromosomal translocation t(10;14)(q24;q11). [Abstract] *11th International Workshop on Human Gene Mapping (HGMII)*, 1991.
40. Sorce L, Li G, Yuan CC, Corpus G, Baker J, Kamel-Reid S, Dubé ID. Expression of HOXII, the oncogene deregulated in t(10;14) T-ALL, causes transforamtion of NIH 3T3 cells and facilitates growth of human leukemic cells in immune-deficient scid mice. [Abstract] *Blood*, 1991;78(16)(Suppl 1)168a.
41. Bienzle, D, Carter, RF, Kamel-Reid, S, Dick, JE, Kruth, SA, Valli, VE, Jacobs, RM, Dubé, ID. Gene transfer in the dog utilizing long-term bone marrow culture and a retroviral vector. [Abstract] *Proceedings of the Annual Meeting of the American College of Veterinary Pathologists*, 1991, pg 20.
42. Dubé ID, Noble L, Kamel-Reid S. Functional studies of HOX11, the homeobox gene involved in the (10;14) translocation of T-cell neoplasias. [Abstract] *Journal of Cellular Biochemistry*, 1992;Suppl 16C:73:M208.
43. Pantalony D, Dubé ID, Kamel-Reid S, Sutton D, Carstairs K. Burkitt's lymphoma of marrow with unusual morphology, cytogenetics, and molecular genetics: Implications for progression. [Abstract] *Canadian Congress of Laboratory Medicine Proceedings*, 1992;007,p39.
44. Pinkerton PH, Reis MD, DeCoteau J, Srigley JR, Dubé ID. Lineage specific translocation as an early event in lymphomagenesis. [Abstract] *Proceedings of the International Society of Hematology*, 1992;42,p88.
45. Sheer GD, Reis MD, Pinkerton PH, Kamel-Reid S, Dubé ID. Phenotypic heterogeneity among malignant lymphomas with translocations involving the c-myc gene. [Abstract] *Canadian Congress of Laboratory Medicine Proceedings*, 1992;005,p38.
46. Dubé ID, Kamel-Reid S, Kruth SA, Bienzle D, Abrams-Ogg ACG, Carter RF, Dick JE, Ackland-Snow J, Jacobs RM. Retrovirally mediated transfer of a reporter gene into canine pluripotent hematopoietic progenitors; gene transfer and expression without selection or marrow ablative conditioning. [Abstract] *American Journal of Human Genetics*, 1992;51:A213.
47. Dubé ID, Kamel-Reid S, Kruth SA, Bienzle D, Abrams-Ogg ACG, Carter RF, Dick JE, Ackland-Snow J, Jacobs RM. Gene transfer into canine hematopoietic

- progenitors in long-term marrow cultures. [Abstract] *Journal of Cellular Biochemistry*, 1993;Suppl. 17E:SZ206,p230.
48. Dubé ID, Kamel-Reid S, Kruth SA, Bienzle D, Abrams-Ogg ACG, Ackland-Snow J. In vitro activation of hematopoietic progenitors with extensive capacities for in vivo proliferation. [Abstract] *Blood*, 1993;Suppl 1:82(10),586a.
  49. Wells RA, Hummel JL, Kamel-Reid S, Dubé ID. Molecular analysis of a variant translocation in APL; evidence for dysregulation of *RARA* via recombination with a novel locus on chromosome 5. [Abstract] *Proceedings of the American Association for Cancer Research, Conference on Oncogenes and Antioncogenes in Differentiation, Development, and Human Cancer*, Big Sky, Montana, February 1993.
  50. Lichty BD, Corpus G, Noble LM, Dubé ID, Kamel-Reid S. Molecular characterization of a translocation breakpoint in a neuroblastoma-derived cell line bearing a t(1;10)(p32;q24). [Abstract] *Proceedings of the American Association for Cancer Research, Conference on Oncogenes and Antioncogenes in Differentiation, Development, and Human Cancer*, Big Sky, Montana, February 1993.
  51. Ackland-Snow J, Lichty B, Noble L, Dubé ID, Kamel-Reid S. Comparison of four *HOX11* cDNAs and derivation of a consensus sequence. [Abstract] *Proceedings of the American Association for Cancer Research, Conference on Oncogenes and Antioncogenes in Differentiation, Development, and Human Cancer*, Big Sky, Montana, February 1993.
  52. Noble L, Bryce DM, Breitman ML, Dardick I, Kamel-Reid S, Dubé ID. *HOX11* is weakly transforming in NIH3T3 fibroblasts and causes B-lymphoid hyperplasia in *HOX11* transgenic mice. [Abstract] *Proceedings of the American Association for Cancer Research, Conference on Oncogenes and Antioncogenes in Differentiation, Development, and Human Cancer*, Big Sky, Montana, February 1993.
  53. Lichty BD, Kamel-Reid S, Dubé ID. Characterization of a translocation involving a human homeobox gene promoter region in a neuroblastoma. [Abstract] *NCI-C New Directions in Cancer Research Symposium*, Honey Harbor, September 1993.
  54. Hummel JL, Wells RA, Dubé ID, Kamel-Reid S. Molecular characterization of pediatric APL, involving a novel variant translocation, t(5;17). [Abstract] *NCI-C New Directions in Cancer Research Symposium*, Honey Harbor, September 1993.
  55. Ackland-Snow J, Dubé ID, Kamel-Reid S. Activation of pluripotent haematopoietic stem cells in long term marrow cultures. [Abstract] *NCI-C New Directions in Cancer Research Symposium*, Honey Harbor, September 1993.
  56. Dubé ID, Kamel-Reid S, Kruth SA, Bienzle D, Abrams-Ogg ACG, Ackland-Snow J. In vitro activation of hematopoietic progenitors with extensive capacities for in vivo proliferation. [Abstract] *Blood*, 1993;(Suppl1):82(10),16a.
  57. Kamel-Reid S, Dubé ID, Dorich R, Hummel J, Reis M, Ackland-Snow J. An immune-deficient mouse model for human chronic lymphocytic leukemia (CLL). [Abstract] *Blood*, 1993;(Suppl 1):82(10),568a.

58. Ackland-Snow J, Dubé ID, Kamel-Reid S. Adoptive transfer of human long-term marrow culture cells in immune-deficient mice: A model system for gene transfer into hematopoietic progenitors. [Abstract] Journal of Cellular Biochemistry, 1994;(Suppl 18A):DZ300,p236.
59. Lichty BD, Kamel-Reid S, Dubé ID. Molecular characterization of translocation carried by a neuroblastoma-derived cell line involving the promotor region of a homeobox gene. [Abstract] Journal of Cellular Biochemistry, 1994;(Suppl 18A):D102,p192.
60. Hummel J, Wells RA, Kamel-Reid S, Dubé ID. Characterization of a variant pediatric APL; Molecular evidence for dysregulation of RARA by recombination with a novel locus on chromosome 5. [Abstract] Journal of Cellular Biochemistry, 1994;(Suppl 18A): D101, p192.
61. Kirby MA, Kamel-Reid S, Dubé ID, Luke BK, Zipursky A, Bence-Bruckler I. An unusual case of congenital acute promyelocytic leukemia with t(11;17) and the presence of retinoic acid receptor-alpha treated with ALL-trans retinoic acid. [Abstract] Proceeding of the American Society of Pediatric Hematology/Oncology, October 1994.
62. Borrow J, Munroe D, Dubé ID, Ohyashiki K, Becher R, Morris CM, Rowley J and Housman DE. Segregation of the AML t(7;11)(p15;p15) translocation chromosomes in somatic cell hybrids. [Abstract] American Journal of Human Genetics, 1994. 55: 3 (Suppl.) A297.
63. Dubé ID. Recent advances in characterizing genes involved in chromosome translocations in cancer. [Abstract] Proceedings of the 1994 Congress of The Canadian Society of Laboratory Technologists, Vancouver, BC, June 1994.
64. Lichty B, Kamel-Reid S, Dubé ID. Molecular characterization of a translocation in a neuroblastoma derived cell line involving the promoter of a homeobox gene. [Abstract] Proceedings of the 1995 Annual Meeting of the Clinical Research Society of Toronto, Toronto, Ontario, April, 1995.
65. Chu P, Kamel-Reid S, Dubé ID. Gene therapy for hADA deficiency: Ex vivo retroviral gene transfer of hADA into human hematopoietic stem cells targeted in long-term bone marrow cultures. [Abstract] Proceedings of the 1995 Annual Meeting of the Clinical Research Society of Toronto, Toronto, Ontario, April, 1995.
66. Lutzko C, Kruth S, Abrans-Ogg A, Clark B, Shull R, Kohn D, Danos O, Kamel-Reid S, Dubé ID. Gene therapy for mucopolysaccharidosis type I - Preclinical studies in a canine model for MPSI. [Abstract] Proceedings of the 1995 Annual Meeting of the Clinical Research Society of Toronto, Toronto, Ontario, April, 1995.
67. Prince HM, Stewart AK, Sutherland DR, Cappe D, Nanji S, Dubé ID. Retroviral mediated gene transfer in multiple myeloma. [Abstract] Proceedings 5th International Workshop on Multiple Myeloma, Le Baule, France, July, 1995.
68. Harrison KJ, Sher G, Dubé ID. Heterogeneity in the 3q21/3q26 syndrome of ANLL. [Abstract] Proceedings of the 1995 Great Lakes Chromosome Conference, Toronto, Ontario, May, 1995.

69. Dubé ID, Brennan S, Johnson S, Chiang P, Derbyshire D, Stuart E, Huang L. [Abstract] *Proceedings of the 1995 Great Lakes Chromosome Conference*, Toronto, Ontario, May, 1995.
70. Dubé ID. Molecular cancer cytogenetics. [Abstract] *Proceedings of the 1995 Annual Meeting of the American Association of Cytogenetic Technologists*, San Antonio, Texas, June, 1995
71. Dubé ID, Stewart AK, Lutzko C, Kruth S, Abrams-Ogg A, Shull R, Danos O, Kohn D, Reddy V, Chu P, Kamel-Reid S. [Abstract] Gene transfer into marrow-derived hematopoietic stem cells. *Gene Therapy*, 1995; 2:579.
72. Prince HM, Stewart AK, Dubé ID. Retroviral mediated gene transfer in multiple myeloma. [Abstract] *Clinical and Investigative Medicine*, 1995;18:4 (Suppl.), 443.
73. Imrie K, Dubé ID, Colwill R, Prince M, Keating A. New clonal cytogenetic abnormalities detected after autologous bone marrow transplantation (ABMT) for acute myeloid leukemia (AML) may not confer an adverse prognosis. [Abstract] *Clinical and Investigative Medicine*, 1995; 18:4 (Suppl.), 447.
74. Stewart AK, Dubé ID. Monitoring cancer relapse with retroviral gene marked autologous blood or bone marrow cells. What have we learned and what next? [Abstract] *Gene Therapy*, 1995;2:590.
75. Lutzko C, Kruth S, Abrams-Ogg A, Clark B, Kohn D, Danos O, Shull R, Dubé ID. Gene transfer of the  $\alpha$ -iduronidase cDNA into MPS 1 canine bone marrow cells. [Abstract] *Proceedings of Keystone Symposia on Gene Therapy for Hematopoietic Stem Cells in Genetic Disease and Cancer*, Taos, New Mexico, February, 1996.
76. Shull R, Lu X, Lutzko C, Kruth S, Dubé ID, Millan R, Carter S, Goehle S, Kime HP, Schuening F, Salvetti A, Danos O, Kohn D. Multicentre study of gene therapy in canine MPS 1. [Abstract] *Proceedings of Keystone Symposia on Gene Therapy for Hematopoietic Stem Cells in Genetic Disease and Cancer*, Taos, New Mexico, February, 1996.
77. Hudoba M, Lutzko C, Kruth S, Abrams-Ogg A, Jordan C, Clarke JTR, Dubé ID, Preclinical studies of gene therapy for Gaucher disease. [Abstract] *1996 Annual Meeting of The Clinical Research Society of Toronto*, Toronto, Ontario, April 1996.
78. Lutzko C, Kruth S, Abrams-Ogg A, Lau K, Dubé ID. Gene therapy for canine MPS1. [Abstract] *The Canadian Society for Mucopolysaccharidosis and Related Diseases Newsletter*. Summer, 1996.
79. Hudoba M, Lutzko C, Kruth S, Abrams-Ogg A, Jordan C, Clarke JTR, Dubé ID. In vitro and in vivo preclinical studies of gene therapy for Gauher Disease. [Abstract] *Clinical and Investigative Medicine*, 19;4(Suppl.)S29; 1996.
80. Omori F, Kruth S, Abrams-Ogg A, Lutzko C, Reis M, Pinkerton P, Catzavelos C, Lau K, Dobson H, Gartley C, Ruedy C, Nanji S, Krygsman P, McGarrity G, Stewart AK, Dubé ID. Extensive in vivo proliferation of genetically modified human hematopoietic stem cells engrafted in pre-immune canine fetuses. [Abstract] *Blood*, 1996; 88(10)(Suppl.1) 270a.
81. Lutzko C, Kruth S, Abrams-Ogg A, Lau K, Lu X, Shull R, Danos O, Kohn D, Dubé ID. Gene therapy for an enzyme deficiency state is abrogated by immune

- responses to gene modified hematopoietic stem cells. [Abstract] *Blood*, 1996;88(10)(Suppl.1),274a.
82. Stewart AK, Nanji S, Krygsman P, Ruedy C, Singaraja S, Nayar R, Peck B, Sutherland DR, McGarrity G, Dubé ID. Engraftment of gene marked long term marrow culture (LTMC) cells in myeloma patients. [Abstract] *Blood*, 1996;88:10 (Suppl.1),270a.
83. Reddy V, Stewart AK, Prince HM, Messner H, Nanji SL, Wild AP, Ruedy CM, Singaraja RR, Chu P, Lutzko CM, Dubé ID. Human hematopoietic progenitors in long term marrow cultures (LTMC) are amenable to retroviral mediated gene transfer. [Abstract] *Clinical and Investigative Medicine*, 19:4(Suppl)S103;1996.
84. Buckstein R, Crump M, Dubé ID, Scott JG, Sutton DMC, Stewart AK, Pantalony D, Carstairs K, Baker M, Keating A. Prognostic factors in myelodysplastic syndromes: The Toronto Hospital experience. [Abstract] *Clinical and Investigative Medicine*, 19:4(Suppl.)S35,1996.
85. Dubé ID, Stewart AK. Human hematopoietic stem cell gene transfer using long-term marrow culture cells. [Abstract] *Journal of Hematotherapy*, 1997, 6:4, 368.
86. Stewart AK, Trudell S, Buckstein R, Dubé ID, Nanji S, Nayar S, Dodgson C, Dessureault S, Gallenger S, Graham FL, Hawley RG, Thomas T, Sutherland DR. Plasma cell vaccine production: Negative selection, adenoviral infection and in vivo expression of vector derived interleukin 2 (IL-2). [Abstract] *Blood*, 1997;90:10 (Suppl.1),1599.
87. Simpson DR, Berkahn LC, Squire J, Meharchand J, Dubé ID, Sutton DM, Crump RM, Keating A, Stewart AK. Prognostic significance of cytogenetics in patients with multiple myeloma referred for autologous stem cell transplant (ABMT). [Abstract] *Blood*, 1997;90:10 (Suppl.1),2349.
88. Tisdale JF, Stewart AK, Dickstein B, Dubé ID, Cappe D, Dunbar CE, Brown KE. Human herpesvirus 8 in patients with multiple myeloma. [Abstract] *Blood*, 1997;90:10(Suppl 1),2614.
89. Berkahn LC, Simpson DR, Squire J, Dubé ID, Meharchand J, Sutton DM, Stewart AK. Cytogenetic analysis of patients with multiple myeloma referred for ABMT. [Abstract] *Blood*, 1997;90:10(Suppl.1),4077.
90. Kruth S, Abrams-Ogg A, Lutzko C, Lau K, Ruedy C, Catzavelos C, Lu X, Shull R, Dubé ID. Retroviral-mediated gene therapy of canine mucopolysaccharidosis 1. [Abstract] *Journal of the American College of Veterinary Internal Medicine*, 1997;11:132.
91. Dubé ID, Hough MR, Reis MD. HOX11, a homeodomain-containing transcription factor dysregulated in the t(10;14) translocation of lymphoid malignancy, induces B-lymphoid malignancies in IgH $\mu$ -HOX11 transgenic mice. [Abstract] *Experimental Hematology*; 1998;25:8,253.
92. Buckstein R, Imrie K, Spaner D, Potichnyj A, Robinson JB, Nanji S, Pennel N, Reis M, Pinkerton P, Dubé ID, Hewitt K, Berinstein NL. The effects of in vivo purging with rituxan on stem cell mobilization efficacy, harvest purity, cytokine profile and engraftment in patient's with relapsed follicular lymphoma undergoing autologous stem cell transplant. [Abstract] *Blood*, 1998; 92(10) Suppl 1,2672.

93. Buckstein R, Imrie K, Spaner D, Reis M, Pinkerton P, Dubé ID, Coovadia A, Richardson P, Lima A, Hewitt K, Berinstein NL. DMSO is not toxic to hematopoietic stem cells. [Abstract] *Blood*, 1998; (92(10) Suppl 1, 4285.
94. Kamel Reid S, Hummel JL, Wells RA, Dubé ID, Licht JD. Deregulation of NPM and PLZF in a variant t(5;17) case of acute promyelocytic leukemia. [Abstract] *Blood*, 1998; 92(10) Suppl 1, 864.
95. Dubé ID, Hough MR, Reis MD. HOX11, a homeodomain-containing transcription factor dysregulated in the t(10;14) translocation of T-ALL, induces B-lymphoid malignancies in IgH $\mu$ -HOX11 transgenic mice. [Abstract] *Proceedings of the 27th Annual Meeting of the International Society for Experimental Hematology*, Vancouver, B.C., 1998.
96. Hough MR, Reis MD, Dubé ID. HOX11, a homeodomain-containing transcription factor dysregulated in the t(10;14) translocation of T-ALL, induces B-lymphoid malignancies in IgH $\mu$ -HOX11 transgenic mice. [Abstract] *Proceedings of the Annual Meeting of the Royal College of Physicians and Surgeons of Canada*, Toronto, Ontario, 1998.
97. Lutzko C, Kruth S, Abrams-Ogg A, Li L, Shull R, Dubé ID. Gene therapy for canine mucopolysaccharidosis 1 (MPS 1) adoptive transfer of genetically corrected hematopoietic progenitors to adult or fetal MPS 1 recipients results in engraftment but not amelioration of disease. [Abstract] *Proceedings of the 2nd Annual Meeting of the American Society of Gene Therapy*, 1999, 71a.
98. Hough MR, Rosic-Kablar S, Reis MD, Dubé ID. HOX11 transgenic mice as a model system for assessing immunotherapeutic protocols for nonfollicular B-lineage lymphoma. [Abstract] *Proceedings of the Cancer Biology and the Mutant Mouse: New Methods, New Insights*, AACR, Keystone, 1999, A29.
99. Viani M, Dubé ID, Lim MS. Bone marrow stromal cell expression of matrix metalloproteinases and their inhibitors is regulated by cytokines and growth factors. [Abstract] *Blood*, 1999; 94:10 (Supl 1), p168b
100. Juopperi T, Omori F, Chan C, Zhao Y, Stewart AK, Dubé ID. Retroviral-mediated transfer and expression of the multidrug resistance protein 1 (MRP1) gene protects human hematopoietic cells from antineoplastic drugs. [Abstract] *Blood*, 1999; 94:10 (Supl 1), p411b.
101. Juopperi TA, Stewart AK, Kruth S, Chan CK, Li L, Abrams-Ogg A, Woods P, Dubé ID. Retroviral-mediated gene transfer and expression of the multidrug resistance protein 1 (MRP1) for hematopoietic chemoprotection: Preclinical studies in a canine model. [Abstract] *Molecular Therapy*; 2000;1:5;pS89, #215.
102. Rosic-Kablar S, Chan K, Dubé ID, Hough MR. Lymphomas spontaneously arising in HOX11 transgenic mice express tumor antigens that induce T cell responses in healthy mice but not during the terminal stages of lymphomagenesis: Implications for lymphoma immunotherapy. [Abstract] *Proceedings of the 2000 Keystone Symposia*, January 2000,
103. Hough MR, Rosic-Kablar S, Chan K, Dubé ID. Dendritic cells presenting antigens derived from apoptotic lymphoma cells are potent activators of immune responses. [Abstract] *Proceedings of the 2000 Keystone Symposia*, January 2000.

104. Chen E, Lim MS, Rosic-Kablar S, Chan K, Dubé ID, Hough MR. Acceleration of B cell lymphomagenesis in HOX11-transgenic mice by the murine AIDS (MAIDS) virus. [Abstract] Blood, 2000, 96:11, p 339a.
105. Hough, MR, Chen E, Lim MS, Dubé ID. Insertional mutagenesis by the murine AIDS virus accelerates lymphomagenesis in HOX11 transgenic mice. [Abstract] Proceedings of the 2001 Keystone Symposia, January 2001, 39:104.
106. Hough MR, Rosic-Kablar, S, Chan, K, Dubé ID. Dendritic cells presenting antigens derived from apoptotic lymphoma cells are potent activators of immune responses. [Abstract] Proceedings of the Keystone Symposium, Cellular Immunity and Immunotherapy of Cancer. 74:127, 2000.
107. Chen E, Rosic-Kablar S, Lim MS, Chan K, Dubé ID, Hough, MR. Acceleration of B cell lymphomagenesis in HOX11-transgenic mice by proviral disruption of the Ubr1 gene. [Abstract] Proceedings of the American Association of Cancer Research Conference: Ubiquitination in Normal and Cancer Cells. 30, 2002.
108. Hough, MR Chen E, Rosic-Kablar S, Lim MS, Dubé ID. Loss of Ubr1 synergizes with loss of the Hox11 gene. [Abstract] Proceedings of the American Association of Cancer Research Conference: Ubiquitination in Normal and Cancer Cells. 30, 2002.
109. Rosic-Kablar S, Mileikovskaia M, Gartley C, Kruth SA, Dubé ID, Nagy A, Hough MR. Generation of canine embryonic stem cells for use in animal models of human single gene disorders. [Abstract] Proceedings of the Keystone Symposia: From Stem cells to Therapy. Steamboat Springs, Colorado; 2003
110. Rosic-Kablar, S, Lim M, Dubé ID, Hough MR. Induction of immune responses mediated by dendritic cells cross-presenting lymphoma cell antigens. [Abstract] Proceedings of the Annual Meeting of The American Association of Cancer Research. Toronto, Canada: Proc Am Assoc Cancer Res 40:1833, 2003.
111. Chen E, Rosic-Kablar S, Lim MS, Chan K, Dubé ID, Hough, MR. Acceleration of B cell lymphomagenesis in HOX11-transgenic mice by proviral disruption of the Ubr1 Gene. [Abstract] Proceedings of the Annual Meeting of The American Association of Cancer Research. Toronto, Canada: Proc Am Assoc Cancer Res 40: 4828, 2003.
112. Grantab R, Rosic-Kablar S, Gong B, Dubé ID, Hough M. Canine side population cells: future potential for stem-cell based therapies. [Abstract] Proceedings of the Annual Meeting of The American Association of Cancer Research. Toronto, Canada: Proc Am Assoc Cancer Res 40: 4331, 2003.
113. Hough MR, Rosic-Kablar S, Mileikovskaia M, Gartley C, Kruth SA, Dubé ID, Nagy A. Generation of canine embryonic stem cells for use in animal models of human single gene disorders. [Abstract] Proceedings of The Annual Meeting of The American Society of Gene Therapy, Washington DC, Molecular Therapy 7: 1008, S388, 2003.
112. Hough MR. Rosic-Kablar S, Mileikovskaia M, Gong B, Vintersten K, Dubé ID, Kruth SA, Gartley C, Nagy A. [Abstract] Generation of canine embryonic stem cells for use in animal models of human disease. (Proceeding of the 2003 Annual Meeting of The American Society of Hematology).

**E Non-Refereed Publication (Book Chapters)**

1. Dubé ID, Kalousek DK, Coulombel L, Eaves CJ, Eaves AC. In vitro cytogenetic studies in chronic myeloid leukemia (CML). In: Salmon SE, and Trent JM, eds. *Human Tumor Cloning*. New York: Grune & Stratton, 1984:119-132.
2. Dubé ID, Kalousek DK, Coulombel L, Eaves CJ, Eaves AC. Variation in Ph1-positive progenitor maintenance in long-term CML marrow cultures. In: Bishop JM, Rowley JD, and Greaves M., eds. *Genes and Cancer*. UCLA Symposium on Molecular and Cellular Biology, New Series. New York: Alan R. Liss, Inc., 1984:17:639-650.
3. Coulombel L, Eaves CJ, Dubé ID, Kalousek DK, Eaves AC. Variable persistence of leukemic progenitor cells in long-term CML and AML marrow cultures. In: Wright DG, and Greenberger JS, eds. *Long-Term Bone Marrow Culture: Present Experience and Future Possibilities*. New York: Alan R. Liss, Inc., 1984:243-254.
4. Eaves C, Coulombel L, Dubé ID, Kalousek D, Cashman J, Eaves A. In: Palek, J. ed. Maintenance of normal and abnormal hemopoietic cell populations in long-term cultures of CML and AML marrow cells: *Hematopoietic Stem Cell Physiology*. New York: Alan R. Liss, Inc., 1985:403-413.
5. Eaves C, Coulombel L, Dubé ID, Kalousek D, Cashman J, Eaves A. In: Neth, Gallo, Greaves, Janka eds. Behavior of human leukemic progenitor populations in long-term marrow culture: *Hematology and Blood Transfusion: Modern Trends in Human Leukemia VI*. Berlin: Springer-Verlag, 1985;29:163-167.
6. Dubé ID, Carter RF, Pinkerton PH. Chromosome abnormalities in chronic myeloid leukemia. A model for acquired chromosome changes in hematological malignancy. p.3-24. In: *Genetic Markers of Haematological Malignancy*. PH Pinkerton and MD Reis (eds). Karger, New York, 1990.
7. Dubé ID. Gene transfer into marrow-derived hematopoietic stem cells. In: *Gene Delivery Systems - A state-of-the-art review*. OECD Documents, Paris, France, 1996; 183-193.
8. Dubé ID, Cournoyer D. Gene therapy: Here to stay. In: *Gene Delivery Systems - A state-of-the-art review*. OECD Documents, Paris, France, 1996; 403-418. (Originally published in Canadian Medical Association Journal, 1995;152(10):1605-1613.)
9. Allan D, Dubé ID. Gene therapy: Future prospects. In: *Gene Therapy: Current Status, Future Prospects*. G. Rock (ed.) Pergamon Press. Elsevier Science Inc., NY, USA, 1996; 17:1, 203-205.
10. Lutzko C, Chu P, Dubé ID. Gene transfer into hematopoietic stem cells: Future prospects. In: *Gene Therapy: Current Status, Future Prospects*. G. Rock (ed.) Pergamon Press, Elsevier Science Inc., NY, USA, 1996; 17:1, 129-136.
11. Dubé ID, Stewart K. Adoptive transfer of genetically modified hematopoietic stem cells: Future prospects. In: *Gene Therapy: Current Status, Future Prospects*. G. Rock (ed.) Pergamon Press, Elsevier Science Inc., NY, USA, 1996, 17;1, 137-145.
12. Stewart K, Prince HM, Dubé ID. Background and update to a phase 1 trial of stem cell gene marking in multiple myeloma: Future prospects. In: *Gene*

- Therapy: Current Status, Future Prospects*. G. Rock (ed.) Pergamon Press. Elsevier Science Inc., NY, USA, 1996, 17:1, 175-184.
13. Dubé ID. Guest editorial: Gene Therapy in Canada. *Gene Therapy: Current Status, Future Prospects*. G. Rock (ed.) Pergamon Press, Elsevier Science Inc. NY, USA, 1996, 17:1, 3-5.
  14. Stewart AK, Dubé ID, Hawley RG. Gene marking and the biology of hematopoietic cell transfer in human clinical trials. *Blood Cell Biochemistry*, L.Fairbairn, N.Testa (eds.), Kluwer Academic/Plenum Publishers, NY, USA, 1999, 8: 243-268.

**F** **Books Edited:**

1. Gene Therapy: Current Status, Future Prospects. Dubé ID, Pergamon Press, Elsevier Science Inc: pp. 206, Oxford, UK.,1996.

**G.** **Papers Presented:**

1. Dubé ID, Eaves AC, Eaves CJ. A new technique for the cytogenetic analysis of cells from single hemopoietic colonies of bone marrow or peripheral blood origin. Presented to the American Society of Human Genetics Annual Meeting, New York, September 25th, 1980.
2. Dubé ID. Normal stem cells in CML. Presented at the Cancer Control Agency of British Columbia, Vancouver, B.C., October 10th, 1983.
3. Dubé ID. In vitro cytogenetic studies in CML. Presented at the Fourth Conference on Human Tumor Cloning, Tucson, Arizona, January 8th, 1984.
4. Dubé ID. Deletion in the short arm of chromosome 9 in childhood acute lymphoblastic leukemia (ALL) without lymphomatous features. Presented at the Annual Meeting of the Genetics Society of Canada, London, Ontario, June 27th, 1985
5. Dubé ID. Translocation t(10;14) in T-cell neoplasia. Presented to the Department of Cytogenetics and Immunology. The Royal Marsden Hospital, London, England, April 17th, 1986.
6. Dubé ID. A putative oncogene at chromosomal band 10q24. Presented at the Great Lakes Chromosome Conference, Toronto, Ontario, May 21st, 1986.
7. Dubé ID. Molecular dissection of the 10;14 translocation in T-cell neoplasia. Presented at the Annual Meeting of the Clinical Research Society of Toronto, March 26th, 1988.
8. Dubé ID, Lu M, Minden M, Raimondi SC, Sutherland PS, Beckett TA. Breakpoints occur within the delta-chain locus of the T-cell receptor gene in the t(10;14)(q24;q11) of T-cell neoplasia. Presented at the Annual Meeting of the American Society of Human Genetics, New Orleans, U.S.A.,October 12th, 1988.
9. Dubé ID, Dixon J, Beckett T, Benn P, McKeithan T. Location of breakpoints within the major breakpoint cluster region (bcr) in 33 patients with bcr rearrangement-positive chronic myeloid leukemia (CML) with complex or absent Philadelphia chromosomes. Presented at the Annual Meeting of the American Society of Human Genetics, Baltimore, USA, November 14th, 1989.
10. Dubé ID, Lu M, Raimondi S, Carroll A, Wu X, Baker J, Hogg D. The TCL3 oncogene is expressed in normal tissue and is dysregulated via recombinase

- mediated recombination in leukemic cells from patients with t(10;14) T-ALL. Presented at the Annual Meeting of the American Society of Hematology, Boston, USA, December 3rd, 1990.
11. Dubé ID. A new human homeobox gene is deregulated in lymphoid neoplasias with the t(10;14)(q24;q11) translocation. Presented at the 2nd Eastern Canadian Conference on Development and Cancer, Montreal, Quebec, September 23rd, 1991.
  12. Dubé ID, Kamel-Reid S, Yuan CC, Wu X, Corpus G, Crist W, Carroll AJ, Baker J. HOX11, a new homeobox gene is deregulated in lymphoid neoplasias with the t(10;14)(q24;q11) translocation. Presented at the 8th International Congress of Human Genetics, Washington, DC, October 8th, 1991.
  13. Sorce L, Li G, Yuan CC, Corpus G, Baker J, Kamel-Reid S, Dubé ID. Expression of HOX11, the oncogene deregulated in t(10;14) T-ALL, causes transformation of N1H 3T3 cells and facilitates growth of human leukemic cells in immune-deficient mice. Presented at the 1991 Annual Meeting of the American Society of Hematology, Denver, Colorado, December 9th, 1991.
  14. Noble L, Kamel-Reid S, Dubé ID. Characterization of HOX11: a new gene involved in human cancer. Presented at the 1992 Annual Meeting of the Clinical Research Society of Toronto, Toronto, Ontario, April 11th, 1992.
  15. Dubé ID. Kamel-Reid S, Kruth S, Bienzle D, Abrams-Ogg ACG. Long-term engraftment of genetically modified stem cells without marrow ablation. Presented at the Second International Conference on Gene Therapy of Cancer, San Diego, California, November 19th, 1993.
  16. Dubé ID. Gene transfer into hematopoietic stem cells and adoptive transfer in the absence of myeloablation. Presented at the Septièmes entretiens Jacques Cartier Colloque sur la thérapie génique, Annecy, France, December 1, 1994.
  17. Dubé ID. Gene transfer into marrow derived hematopoietic stem cells. Presented at the OECD Workshop on Gene Delivery Systems, Ottawa, Canada, June 27, 1995.
  18. Dubé ID. Ex vivo activation of hematopoietic stem cells facilitates transduction and adoptive transfer. Presented at the First Conference on Stem Cell gene Therapy: Biology and Technology, Chevy Chase, Maryland, September 28, 1995.
  19. Dubé ID. Adoptive transfer of long-term marrow culture cells. Presented at the 1996 Keystone Symposia on Gene Therapy for Hematopoietic Stem Cells in Genetic Disease and Cancer. Taos, New Mexico, February 5, 1996.
  20. Dubé ID. Early results from a clinical trial of stem cell marking in multiple myeloma. Presented at the 1996 European Working Group on Gene Therapy Workshop on Gene Therapy of the annual meeting of the European Hematology Association. Paris, France, May 29th, 1996.
  21. Dubé ID. In utero gene transfer in a canine model. Presented at the NIH symposium on in utero stem cell transplantation and gene therapy. Reno, Nevada. September 10th, 1996.
  22. Dubé ID. Gene marking of cells using long term marrow culture. Presented at the AACR Second Annual Meeting of the American Society of Blood and Marrow Transplantation, San Diego, California, October 2nd, 1996.

23. Dubé ID. Blood progenitor cells for gene therapy. Presented at the Boden Conference on Gene Therapy, Australia, February 4-7, 1997.
24. Dubé ID. Overview of Gene therapy. Presented at the Canadian College of Medical Geneticists Scientific Symposium, Victoria, B.C. September 1997.
25. Dubé ID. Experience with stromal-based system for human and canine gene transfer. Presented at the 2nd Conference on Stem Cell Gene Therapy. Orcas Island, Washington. May 31, 1998.
26. Dubé ID. Pre-clinical and clinical studies of hematopoietic stem cell gene transfer. Presented at the 25th Anniversary of the Dept. of Medical Genetics, University of British Columbia; Vancouver, B.C. June 6, 1998.
27. Dubé ID, Hough MR, Reis MD. HOX11, a homeodomain-containing transcription factor dysregulated in the t(10;14) translocation of lymphoid malignancy, induces B-lymphoid malignancies in IgH $\mu$ -HOX11 transgenic mice. Presented at the 27th Annual Meeting of International Society for Experimental Hematology, Vancouver, B.C. August 1-5, 1998.

**H. Lectures Invited**

1. Dubé ID. A reliable method for the cytogenetic analysis of individual hemopoietic colonies and its potential applications. Guest Lecture, The Department of Genetics University of Gothenburg, Sweden, August 21st, 1981.
2. Dubé ID. Chromosome as in-vitro markers in CML. Presented at the Cancer Control Agency of British Columbia, Vancouver, B.C. June 8th, 1982.
3. Dubé ID. In-vitro cytogenetic studies in CML. Presented at Medical Genetics Rounds, The B.C. Children's Hospital, Vancouver, B.C., December 9th, 1983.
4. Dubé ID. In-vitro cytogenetic studies in CML. Presented at Medical Genetics Rounds, The Alberta Children's Hospital, Calgary, December 12th, 1983.
5. Dubé ID. Stem cell concepts in tumor cytogenetics. Presented at the Canadian Society of Laboratory Technologists, National Congress, Vancouver, B.C., June 18th, 1984.
6. Dubé ID. Cytogenetic findings in Turner Syndrome. Presented at Grand Rounds, The Hospital for Sick Children, Toronto, Ontario, August 22nd, 1984.
7. Dubé ID. Stem cell concepts and tumor cytogenetics - In vitro studies in CML. Presented at Genetics Rounds, The Hospital for Sick Children, Toronto, Ontario, October 24th, 1984.
8. Dubé ID. Prognostic value of cytogenetic changes in malignancies. Presented to the Canadian College of Medical Geneticists, Annual Meeting, Banff, Alberta, February 8th, 1985.
9. Dubé ID. Tumor cytogenetics and stem cell concepts - In vitro studies in CML. Guest lecture, The Lady Davis Institute, The Montreal Jewish General Hospital, Montreal, Quebec, March 29th, 1985.
10. Dubé ID. Normal stem cells in CML. Guest Lecture, the McGill Cancer Center, Montreal, Quebec, March 29th, 1985.
11. Dubé ID. Chromosome of solid tumors. Guest Lecture, Division of Cytogenetics, The Toronto Institute of Medical Technology, Toronto, Ontario, April 12th, 1985.

12. Dubé ID. Prognostic value of chromosomal changes in hematological malignancies. Presented at Cytogenetics Rounds, The Toronto General Hospital, Toronto, Ontario, May 2nd, 1985.
13. Dubé ID. Chromosomal changes in malignant disease. Presented at Immunology Rounds, The Hospital for Sick Children, Toronto, Ontario, May 2nd, 1985.
14. Dubé ID. Prognostic value of karyotype in childhood ALL. Presented at Hematology/Oncology Rounds, The Hospital for Sick Children, Toronto, Ontario, June 6th, 1985.
15. Dubé ID. Normal hemopoietic stem cells in Philadelphia positive CML. Guest Lecture. Presented at the St. Jude Children's Research Hospital, Memphis, Tennessee, June 16th, 1985.
16. Dubé ID. Chromosome changes in cancer. Presented at the Pathology Lecture Series. Women's College Hospital, Toronto, Ontario, October 21st, 1985.
17. Dubé ID. Chromosome in cancer. Implications from studies in childhood leukemia. Presented at University Area Oncology Rounds, The Hospital for Sick Children, Toronto, Ontario, November 15th, 1985.
18. Dubé ID. A new oncogene in T-cell neoplasia? Presented at Hematology Rounds, The Hospital for Sick Children, Toronto, Ontario, November 28th, 1985.
19. Dubé ID. Cytogenetics in Haematology/Oncology. Sixth Haematology Basic Seminar. Presented at Toronto General Hospital, Toronto, Ontario, March 5th, 1986.
20. Dubé ID. Leukemia cytogenetics: Pathogenesis, prognosis and the HSC experience. Presented at Genetics Rounds, The Hospital for Sick Children, Toronto, Ontario, March 29th, 1986.
21. Dubé ID. Cytogenetic studies in hematological malignancies. Presented at North York General Hospital, Toronto, Ontario, March 27, 1986.
22. Dubé ID. Leukemia cytogenetics: Implications of pathogenesis and prognosis. Presented at the Manitoba Institute of Cell Biology, Winnipeg, Manitoba, April 3rd, 1986.
23. Dubé ID. Chromosome abnormalities in T-cell neoplasia. Presented at Immunology Rounds, The Hospital for Sick Children, Toronto, Ontario, April 9th, 1986.
24. Dubé ID. Lymphoma Cytogenetics. Presented at Hematology Rounds, The Wellesley Hospital, Toronto, Ontario, February 13th, 1987.
25. Dubé ID. Leukemia Cytogenetics. Presented at Leukemia Rounds, The Princess Margaret Hospital, Toronto, Ontario, March 30th, 1987.
26. Dubé ID. Cytogenetics in CML. Presented at Hematology Rounds, The Toronto Western Hospital, Toronto, Ontario, April 13th, 1987.
27. Dubé ID. Cytogenetics in Hematological Malignancy. Presented at Oncology Rounds, The Bayview Clinic, Sunnybrook Medical Centre, Toronto, Ontario, April 15th, 1987.
28. Dubé ID. Molecular Biology of CML. Presented at City Wide Hematology Rounds, The Academy of Medicine, Toronto, Ontario, May 6th, 1987.

29. Dubé ID. Molecular Diagnosis in Oncology. Presented at the Annual Meeting of the Ontario Medical Association, The Ontario Hospitals Association, Toronto, Ontario, May 27th, 1987.
30. Dubé ID, and Keating, A. Cancer Cytogenetics. Presented at Grand Medical Rounds, Toronto General Hospital, Toronto, Ontario, June 9th, 1987.
31. Dubé ID. Cancer Cytogenetics. Presented at the 1987 University of Toronto Pathology Reunion. The University of Toronto, June 4th, 1987.
32. Dubé ID. Chromosomes in Human Leukemia. Presented at the Canadian Society of Laboratory Technologists, National Congress, Hamilton, Ontario, June 23rd, 1987.
33. Dubé ID. Cancer Cytogenetics. Presented at the University of Toronto, Department of Pathology (PATH 1013H), February 15th, 1988.
34. Dubé ID. Chromosomes of Solid Tumors. Guest Lecture, Division of Cytogenetics. The Toronto Institute of Medical Technology, Toronto, Ontario, May 20th, 1988.
35. Dubé ID. Cytogenetics in Hematology/Oncology. Presented at the 1988 OSMT Convention, Toronto, Ontario, September 21st, 1988.
36. Dubé ID. Cancer Cytogenetics: Service/Research. Presented at the Pathology Lecture Series, University of Toronto, April 24th, 1989.
37. Dubé ID. Chromosomes and cancer. Guest lecture, Department of Pathology, Kingston General Hospital, Kingston, Ontario, May 2nd, 1989.
38. Dubé ID. Location of breakpoints in chromosome 22 in 33 patients with unusual Philadelphia chromosomes. Presented at the Great Lakes Conference, Toronto, Ontario, May 26th, 1989.
39. Dubé ID. Molecular analysis of chromosomal translocations in leukemia. Presented at the Toronto General Hospital Research Day Symposium, Toronto, Ontario, May 30th, 1989.
40. Dubé ID. Cytogenetics in malignant lymphoma. Presented at Hematology Rounds, Toronto General Hospital, Toronto Ontario, June 23rd, 1989.
41. Dubé ID. Cloning and characterization of the putative oncogene involved in the t(10;14) of human T-cell neoplasia. Presented to Genetics Rounds, The Hospital for Sick Children, Toronto, Ontario, September 21st, 1989.
42. Dubé ID. Molecular biology of complex Philadelphia chromosomes. Presented to the Toronto Leukemia Site Group Program, The Delta Chelsea Inn, Toronto, Ontario February 5th, 1990.
43. Dubé ID. Molecular Cytogenetics of leukemia. Presented to Genetics Rounds, McMaster University, Hamilton, Ontario, May 4th, 1990.
44. Dubé ID. Cloning of translocation breakpoints in human lymphoid neoplasia. Presented to Clinical Biochemistry Department Seminar Series, Banting Institute, University of Toronto, May 9th, 1990.
45. Dubé ID and Messner H. Recent advances in chronic myeloid leukemia. Presented to Grand Medical Rounds, Mount Sinai Hospital, Toronto, Ontario, June 13th, 1990.
46. Dubé ID. In search of new oncogenes. Presented to Hematology Rounds, Toronto General Hospital, Toronto, Ontario, June 22nd, 1990.

47. Dubé ID. Solving the TCL3 riddle. Presented at the Great Lakes Chromosome Conference, Toronto, Ontario, May 24th, 1991.
48. Dubé ID. A new gene involved in human acute leukemia. Presented at the Terry Fox Cancer Research and Immunology Seminar Series, The Hospital For Sick Children, Toronto, Ontario, May 29th, 1991.
49. Dubé ID. Cytogenetics in Hematology/Oncology. Presented at the Basic Science Seminar for trainees in Hematology, Toronto General Hospital, Toronto, Ontario, November 27th, 1991.
50. Dubé ID. Molecular Pathology and the Search For New Genes. Presented at Grand Medical Rounds, Sunnybrook Health Science Center, Toronto, Ontario, May 19th, 1992.
51. Dubé ID. Gene Transfer Into Hematopoietic Stem Cells. Presented at Citywide Hematology Rounds, Toronto General Hospital, Toronto, Ontario, May 12, 1993.
52. Dubé, ID. Gene Transfer Into Pluripotent Hematopoietic Stem Cells. Presented at McGill Cancer Center, McIntyre Medical Sciences Building, Montreal, May 28, 1993.
53. Dubé, ID. Gene Transfer Into Pluripotent Hematopoietic Stem Cells. Presented at the Immunology Seminar Series, The Hospital For Sick Children, Toronto, Ontario, June 16th, 1993.
54. Dubé, ID, Kamel-Reid, S. The Cancer Cytogenetics and Molecular Oncology Program. Indications for Testing. Presented at Department of Hematology/Oncology Nursing Staff, The Hospital for Sick Children, Toronto, Ontario, June 15, 1993.
55. Dubé, ID. Gene Transfer into Pluripotent Hematopoietic Stem Cells. Presented to the Immunology Sciences Research Group, Foothills Hospital, Calgary, Alberta, June 28th, 1993.
56. Dubé, ID. Cytogenetics and Molecular Genetics in the Pathophysiology of Myelodysplastic Syndromes. Presented at the Annual Meeting of the Canadian Association of Pathologist, Banff, Alberta, June 28th, 1993.
57. Dubé, ID. From Bedside to Bench; Follow-up of Routine Diagnostic Testing in Lymphoid Neoplasia Gives New Insights into Cancer Biology. Leica Scientific Award presentation. Presented at the Annual Meeting of the Canadian Association of Pathologist, Banff, Alberta, June 29th, 1993.
58. Dubé, ID. Gene Transfer into Hematopoietic Stem Cells. Presented at Progress in Pathology Rounds, Women's College Hospital, Toronto, September 7th, 1993.
59. Dubé ID. Gene Transfer into Hematopoietic Stem Cells. Presented at Genetics Rounds, The Hospital for Sick Children, Toronto, September 30th, 1993.
60. Dubé ID, Kamel-Reid S, Kruth S, Bienzle D, Abrams-Ogg ACG. Long-term engraftment of genetically modified stem cells without marrow ablation. Presented at the Second International Conference on Gene Therapy on Cancer, San Diego, California, November 19th, 1993.
61. Dubé ID, Kamel-Reid S, Kruth S, Bienzle D, Abrams-Ogg ACG, Dick I, Carter R, Ackland-Snow J. In vitro activation of hematopoietic progenitors with extensive capacities for in vivo proliferation. Presented at the 1994 Academic Half-Day in Hematology, Sunnybrook Health Sciences Center, January 29th, 1994.

62. Dubé ID. Stem cell marking in multiple myeloma. Presented to Inex Pharmaceuticals, Vancouver, BC, March 10th, 1994.
63. Dubé ID. Hematopoietic stem cell gene transfer. Presented at Perinatology Research Rounds, The Hospital for Sick Children, Toronto, March 21, 1994.
64. Dubé ID. Gene Transfer into bone marrow. Presented to the Canadian Society for Transfusion Medicine, Annual General Meeting, Montreal, May 15th, 1994.
65. Dubé ID. Gene therapy. Presented at the Second Annual Member Profile Marathon of the Toronto Biotechnology Initiative, Toronto, June 16th, 1994.
66. Dubé ID. Recent advances in characterizing genes involved in chromosome translocations in cancer: An update. Presented at the Canadian Society of Laboratory Technologists, Vancouver, BC., June 1994.
67. Dubé ID. Recent advances in characterizing genes involved in chromosome translocations in cancer. Presented at Victoria General Hospital, July 13th, 1994.
68. Dubé ID. How bad genes can be made good. Presented to the Board of Directors of the Toronto Hospital, July 19th, 1994.
69. Dubé ID. Gene Therapy. Presented at the Pathology Summer Student Series, The Toronto Hospital, July 27, 1994.
70. Dubé ID. Gene Therapy in Canada. Presented at Bionet '94 Conference, Vancouver, B.C., October 13th, 1994.
71. Dubé ID. Canada's First Gene Therapy Trial. Presented to the Biology Department, University of Victoria, B.C., November 3rd, 1994.
72. Dubé ID. Gene transfer into canine hematopoietic stem cells and reconstitution without ablation. Presented at the Gene Therapy Symposium. Center Jacques Cartier and Fondation Marcel Mérioux, Annecy, France, December 1, 1994.
73. Dubé ID. Gene transfer into hematopoietic stem cells. Presented at Somatix Therapy Corporation, Alameda, California, December 15, 1994.
74. Dubé ID. Gene transfer into hematopoietic stem cells. Presented at the Séminaires de L'Institut d'Hématologie Hôpital Saint-Louis, Paris, France, January 30, 1995.
75. Dubé ID. Blood cells: vehicles for gene therapy. Presented at the Division of Cancer Biology Research Seminar Series, Reichmann Research Building, Sunnybrook Health Science Centre, Toronto, February 22, 1995.
76. Dubé ID and Stewart K. Update of the Toronto Hospital's Gene Therapy Trial. Presented at Genetics Rounds, The Hospital For Sick Children, Toronto, May 15th, 1995.
77. Dubé ID. Molecular Cancer Cytogenetics - Recent Advances. Presented at the 25th Annual Meeting of the American Association of Cytotechnologists, San Antonio, Texas, June 2nd, 1995.
78. Dubé ID. Adoptive transfer of genetically modified hematopoietic stem cells. Presented at the June 1995 Toronto Symposium: Gene Therapy in Canada. June 27, 1995.
79. Dubé ID. Gene transfer into hematopoietic stem cells. Presented at the July 1995 Ottawa OECD Workshop on Gene Delivery Methods for Human Gene Therapy. Ottawa, June, 1995.

80. Stewart K and Dubé ID. Prelude to gene therapy: stem cell marking in multiple myeloma - a clinical trial. Presented at City Wide Oncology Rounds, Toronto, September 17, 1995.
81. Dubé ID. An update of The Toronto Hospital clinical gene transfer protocol. Presented at Pathology rounds, Queen's University, Kingston, Ontario, November 21, 1995.
82. Dubé ID. Gene therapy- Part 1. Presented at Oncology Grand Rounds, Sunnybrook Health Science Centre, Toronto, January 24, 1996.
83. Dubé ID. Blood cells for gene therapy. Presented at the Eye Research Institute of Canada, The Toronto Hospital, Western Division, January 26, 1996.
84. Dubé ID. Use of long term bone marrow cultures for transduction of hematopoietic stem cells:*in vivo* studies. Presented at Somatix Therapy Corporation. Alameda, California, March 1, 1996.
85. Dubé ID. Gene transfer into hematopoietic stem cells. Presented at Hematology Rounds, University of British Columbia and Terry Fox Laboratory, Vancouver, B.C., June 20th, 1996.
86. Dubé ID. Gene transfer studies in dogs. Presented at the NIH Symposium on in utero stem cell transplantation and gene therapy. Reno, Nevada. September 11, 1996.
87. Dubé ID. An overview of Gene Therapy. Presented at the Gene Therapy Symposium of the Royal College of Physicians and Surgeons of Canada Annual Meeting. Halifax, Nova Scotia, September 28, 1996.
88. Dubé ID. Activation of hematopoietic stem cells for gene therapy. Presented at Pfizer's Stem Cell Hematopoiesis and Gene Therapy Symposium. La Jolla, California. November 6, 1996.
89. Dubé ID. Gene therapy. Presented at Nesbitt Burns Biotechnology Conference. Toronto, Ontario. November 26, 1996.
90. Dubé ID. Human gene therapy: progress and prognosis. Presented at the Boden Conference on Gene Therapy. Australia, February 4-7, 1997.
91. Dubé ID. In vitro systems for hematopoietic stem cell gene transfer. Presented at the Symposium on Hematopoietic Stem Cells: Biology, Lymphopoiesis and Transplantation of the 1997 Joint Annual Meeting of the American Association of Immunologists. San Francisco, California. February 21-26, 1997.
92. Dubé ID. Long-term marrow cultures activate hematopoietic stem cells for gene transfer. Presented at the 23rd Annual Meeting of the European Group for Blood and Marrow Transplantation. Aix-les-Bains, France. March 23-27, 1997.
93. Dubé ID. Overview of gene therapy. Presented at the National Research Council of Canada, Biotechnology Institute. Montreal, Quebec, May 8, 1997.
94. Dubé ID. Optimization of transfection methods for gene transfer. Presented at the Third Annual Meeting of the International Society of Hematotherapy and Graft Engineering. Bordeaux, France. May 31, 1997 to June 3, 1997.
95. Dubé ID. Gene transfer into hematopoietic stem cells. Presented at the Molecular Biology of Hematopoiesis Symposium. Hamburg, Germany, July 3-6, 1997.
96. Dubé ID. Gene therapy, past and future. Presented at the 3rd Canadian Symposium on Gene Therapy. Montreal, Quebec; June 26-28, 1998.

97. Dubé ID. Fondazione Matarelli Educational Symposium: New Frontiers in Oncology and Hematology. Genetic modification of hematopoietic stem cells. Milan, Italy; November 20-21, 1998.
98. Dubé ID. Gene marking in malignancies. Presented at the Advances in Gene Therapy of Cancer ,1999 Eurocancer Annual Meeting. Paris, France; June 4, 1999.

**I. Graduate and Post Graduate Course Lectures**

1. Dubé ID. Genetics and Cancer. Two lectures in the Terry Fox Course in Basic Science of Oncology. The Ontario Cancer Institute, January 13th and 20th, 1987.
2. Dubé ID. Cancer Cytogenetics. Two hour lecture/seminar in Pathology 1013H, University of Toronto, February 15th, 1988 and March 5th, 1990.
3. Dubé ID. Chromosomal localization of genes. One hour lecture in Molecular Biology Course, Department of Pathology, University of Toronto, March 27th, 1990.
4. Dubé ID. Primary chromosome changes in neoplasia: Clinical significance. One hour Basic Sciences Seminar to Hematology/Oncology residents and fellows, Toronto General Hospital, April 25th, 1990.
5. Dubé ID. Cancer Cytogenetics. One hour academic session presented to Genetics Fellows at The Hospital for Sick Children, May 3rd, 1990.
6. Dubé ID. Cancer Cytogenetics. One hour lecture presented at the Seventh Course in Oncology (NCI-C), Hamilton, Ontario, June 18th, 1990.
7. Dubé ID. Homeobox genes and cancer. One hour academic session presented to Genetics Fellows at The Hospital For Sick Children, May 16th, 1991.
8. Dubé ID. Cytogenetics in Hematological Malignancies. Presented for MDS Laboratories Hematology Symposium, Toronto, Ontario, June 14th-15th, 1991.
9. Dubé ID and Kamel-Reid S. Cytogenetics/Oncogenes. Two-hour lecture presented in Mechanisms of Disease (PAT 1007H), University of Toronto, Department of Pathology. October 25th, 1991.
10. Dubé ID. Cancer Cytogenetics. One hour Basic Sciences Seminar to Hematology/ Oncology residents and fellows, Toronto General Hospital, November 27th, 1991.
11. Dubé ID. A Study of Oncogenes by Analysis of Chromosome Abnormalities. One-hour seminar presented to the Institute of Medical Science, University of Toronto, Toronto, Ontario, December 12th, 1991.
12. Dubé ID. A study of oncogenesis by analysis of chromosome abnormalities. One hour seminar presented to the Institute of Medical Sciences, University of Toronto, Ontario, December 12th, 1991.
13. Dubé ID. Cancer Cytogenetics. Two hour lecture presented in Molecular Biology and Application to Human Disease (PATH 1018H), University of Toronto, Ontario, January 28, 1992.
14. Dubé ID. Cancer Cytogenetics. Two hour lecture presented in Molecular Biology and Application to Human Disease (PATH 1018H), University of Toronto, Ontario, November 24, 1992.

15. Dubé ID. Pathology Residents, The Toronto Hospital. 2-hour Lecture on Cancer Cytogenetics, March 1993.
16. Dubé ID and Kamel-Reid S. Research Orientation. One hour seminar to the Hematology Residents, University of Toronto, September 20th, 1993.
17. Dubé ID. Gene Therapy. Hematology Basic Sciences Seminar. Toronto Hospital, November 24th, 1993.
18. Dubé ID. Acute Lymphoblastic Leukemia with a Genetic Etiology. Hematology/Oncology Teaching Rounds, Mount Sinai Hospital. December 13th, 1993.
19. Dubé ID. Research Orientation. One hour seminar to the Hematology Residents, Toronto General Hospital, September 26th, 1994.
20. Dubé ID. Research Orientation. One hour seminar to the Hematology Residents, Toronto General Hospital, July 31st, 1995.
21. Dubé ID. Stem Cell Gene Therapy. Research Summer Students Seminar 1996. Sunnybrook Health Science Centre. June 10, 1996.
22. Dubé ID. Background and results of a phase 1 clinical trial of retroviral gene marking. The Toronto Gene Therapy Network Monthly Seminar Series. Princess Margaret Hospital, June 18, 1996.
23. Dubé ID. Gene therapy. University of Toronto Summer Student Research Programme 1996. University of Toronto, July 31, 1996.
24. Dubé ID. Gene therapy. Biotechnology in Toronto Workshop. Sponsored by the Economic Development Division, The Municipality of Metropolitan Toronto. March 11, 1997.
25. Dubé ID. Gene therapy pre-clinical and clinical studies. Two-hour lecture in MPL445, Genetic Engineering for Disease. University of Toronto, December 3, 1997.
26. Dubé ID. Overview of gene therapy. Two-hour lecture in PAT1018H, Molecular biology and application to human disease. University of Toronto, April 21, 1998.

**J. Post-Doctoral Fellows**

1. Ronald Carter, DVM, Ph.D. - MRC Post-doctoral Fellow. Primary Supervisor 1987-1991  
Research Topic: Canine Model for Autologous Bone Marrow Transplantation. (Current Position: Director of Cytogenetics, McMaster University Medical Center, Hamilton, Ontario)
2. Ming Lu, Ph.D. Post-doctoral Fellow. Primary Supervisor 1988 - 1990.  
Research Topic: Molecular Characterization of the t(10;14) of T-cell Neoplasia. (Current position: Staff Scientist, San Diego Regional Cancer Center, California, USA.)
3. Fusayuki Omori, M.D.- Post-doctoral Fellow. Primary Supervisor 1996-1998.  
Research Topic: Pre-clinical studies of MDR and MRP gene transfer. (Current Position: Assistant Professor, Dept. of Dermatology, Sapporo University School of Medicine, Japan ).
4. Patrizia Bossolasco, Ph.D. Post-doctoral Fellow. Primary Supervisor 1997-1998. Research Topic: Glucocerbrosidase gene transfer. (Current Position: Staff Scientist, Fondazione Matarelli, Clinica S. Pio X, Milan, Italy.)

**K. Resident/Fellow Teaching/Training**

1. Steven Narod, M.D., Fellow in Clinical Genetics, The Hospital for Sick Children. March - July 1988.
2. Ronald Murphy, M.D. Fellow in Hematology/Oncology, The Hospital for Sick Children. Co-Supervisor, January - June 1988.
3. Brigitte Roland, M.D. Fellow in Clinical Cytogenetics, Alberta Children's Hospital. Rotation in Cancer Cytogenetics for CCMG accreditation, June 1989.
4. Suzanne Lewis, M.D. Fellow in Clinical Genetics, The Hospital for Sick Children and McMaster University. Rotation in Cancer Cytogenetics for CCMG accreditation, October 1989.
5. Felix Couture, M.D. Resident in Hematology, The Toronto General Hospital. Rotation in Cancer Cytogenetics. December, 1989.
6. Judy Chernos, Ph.D. Fellow in Clinical Cytogenetics, Alberta Children's Hospital. Rotation in Cancer Cytogenetics for CCMG accreditation, May 1990.
7. Jordan Herst, M.D. Resident in Hematology, The Toronto General Hospital. Rotation in Cancer Cytogenetics, May 1990.
8. Cory Weigensberg, M.D. Resident in Pathology, The Toronto General Hospital. Rotation in Cancer Cytogenetics, November, 1990.
9. Joanne Dixon, M.D. Fellow in Genetics, The Hospital For Sick Children, Toronto. Rotation in Cancer Cytogenetics, April 1991.
10. Gail Rock, M.D. Resident in Hematology, The Toronto Hospital. Rotation in Cancer Cytogenetics, June 1991.
11. John DeCoteau, M.D. Resident in Hematology, The Toronto Hospital. Rotation in Cancer Cytogenetics, October 1991.
12. Kevin Imrie, MD. Resident in Hematology, The Toronto Hospital. Rotation in Cancer Cytogenetics, February 1992.
13. C.S. Leung, MD. Resident in Hematology, The Toronto Hospital. Rotation in Cancer Cytogenetics, June 1993.
14. K. H. Li, MD. Resident in Hematopathology, The Toronto Hospital. Rotation in Cancer Cytogenetics, November 1993.
15. R. Wells, MD. Medical Resident, The Toronto Hospital, Research Elective. June 1993- August 1993.
16. D. Chadwick, PhD. Clinical Genetics Fellow, The Hospital For Sick Children. Cancer Cytogenetics Rotation, January 1994 - February 1994.
17. I. Al-Hashmi, MD. Fellow in Paediatric Hematology/Oncology, The Hospital For Sick Children. Rotation in Cancer Cytogenetics and Molecular Oncology, February 1994.
18. M. Soares, MD. Resident in Anatomic Pathology, The Toronto Hospital. Rotation in Cancer Cytogenetics, June 1994.
19. David Allan, M.Sc., first year medical student, Queen's University, Toronto. Summer Studentship (MRC), 1994.
20. V. J. Reddy, MD. Resident in Hematology, The Toronto Hospital, Research Elective, July 1994 - October 1994.
21. Karen Harrison, PhD. CCMG trainee in Clinical Cytogenetics. Rotation in Cancer Cytogenetics, September - November 1994.

22. G. Pastolero, MD. Resident in Hematopathology, The Toronto Hospital. Rotation in Cancer Cytogenetics, December, 1994.
23. David Allan, M.Sc., Second year medical student, Queen's University, Toronto. Critical Enquiry Elective, May - July, 1995.
24. Monika Hudoba, MD. Resident in Hematopathology, The Toronto Hospital, Research Elective Year, July, 1995 to June, 1996.

**L. Undergraduate Students Supervised**

1. Constantine Iracleous. B.Sc. Student. Course: Project in Molecular Pathology. PAT410Y. Department of Cellular and Molecular Pathology. University of Toronto. September, 1995 to May, 1996.
2. Michelle Rattan. B.Sc. Student. Course: Project in Laboratory Medicine and Pathobiology- LMP405. Department of Laboratory Medicine and Pathobiology, University of Toronto. September, 1998 to May, 1999.
3. Steven Chan. B.Sc. Student. Course: Project in Laboratory Medicine and Pathobiology-LMP405. Department of Laboratory Medicine and Pathobiology, University of Toronto. September, 1999 to May, 2000.
4. Laura Tsang. B.Sc. Student. Course: Project in Laboratory Medicine and Pathobiology-299Y. Department of Laboratory Medicine and Pathobiology, University of Toronto. May 2000 to August 2000.

**M. Graduate Students Supervised**

1. Otto Sanchez, M.D. Graduate Student (M.Sc.), Department of Pathology, University of Toronto. Co-Supervisor with Dr. E. deHarven, 1988 - 1990.
2. Mary Schnurr, B.Sc. Graduate Student (M.Sc.), Department of Pathology, University of Guelph. Co-Supervisor with Dr. R. Jacobs, 1989 - 1992.
3. Dorothee Bienzle, DVM. Graduate Student (M.Sc.), Department of Pathology, University of Guelph. Thesis committee member [Supervisor; R. Jacobs], 1990 - 1992.
4. Lilly Sorce, B.Sc. Graduate Student (M.Sc.), Department of Pathology, University of Toronto. Co-Supervisor with Dr. S. Kamel-Reid, 1991-1993.
5. Siham Muntasser, M.D., Graduate Student (M.Sc.), Department of Pathology, University of Toronto. Thesis committee member [Supervisor; B. Ngan], 1991-1992.
6. Satyajut Battacharya, BSc. Graduate Student (M.Sc.), Department of Pathology, University of Toronto. Thesis committee member [Supervisor; J. Minta], 1990-1992.
7. Julia Ackland-Snow, B.Sc. Graduate Student (M.Sc.), Department of Pathology, University of Toronto. Co-Supervisor with Dr. S. Kamel-Reid, 1992 - 1994. (Student did not complete - admitted to medical school.)
8. Jeff Hummel, B.Sc. Graduate Student (M.Sc.), Institute of Medical Sciences, University of Toronto. Thesis Supervisor 1992 - 1995.
9. Brian Lichty, B.Sc. Graduate Student (M.Sc.), Department of Pathology, University of Toronto. Co-Supervisor with Dr. S. Kamel-Reid, 1993 - 1995. (Student transferred to sole supervision of S. Kamel-Reid).

10. Peter Chu, B.Sc. Graduate Student (M.Sc.), Department of Pathology, University of Toronto. Thesis supervisor, 1993 - 1995.
11. Sandra Perlikowski, B.Sc. Graduate Student (M.Sc.), Department of Pathology, University of Toronto. Thesis committee member [Supervisor: J. Squire], 1994 - 1995.
12. Monte Gill, M.Sc. Graduate Student (PhD), Department of Pathology, University of Toronto. Thesis committee member, [P. Hamel, Supervisor], 1994 - 1995.
13. Miles Prince, MD. Graduate Student, Monash University, Melbourne, Australia. MD Thesis Co-supervisor with Dr. K. Stewart. 1995-1997.
14. Carolyn Lutzko, B.Sc. Graduate Student (Ph.D.), Department of Cellular and Molecular Pathology, University of Toronto. Thesis Supervisor 1994 - 1999.
15. Elizabeth Plowright, B.Sc. Graduate Student (M.Sc.), Institute of Medical Sciences, University of Toronto. Co-supervisor with Dr. K. Stewart, 1997- 1999.
16. Ninos Yacoub, B.Sc. Graduate Student (M.Sc.). Department of Laboratory Medicine and Pathobiology, University of Toronto. Co-supervisor with C. Catzavelos, 1997-1999.
17. Suzana Rosic-Kablar, M.D., Graduate Student (M.Sc.). Department of Laboratory Medicine and Pathobiology, University of Toronto. Thesis Co-supervisor, 1998-1999.
18. Mervat Kahil, M.D. Graduate Student (M.Sc.), Department of Laboratory Medicine & Pathobiology, University of Toronto. Co-supervisor with Lee Cyn Ang, 1998-1999. (Student did not complete.)
19. Tarja Juopperi, DVM. Graduate Student (M.Sc.) Department of Laboratory Medicine and Pathobiology, University of Toronto. Thesis Co-supervisor, 1998-2000.
20. Mary Anne Viani, Graduate Student (M.Sc.) Department of Laboratory Medicine & Pathobiology, University of Toronto. Co-supervisor with M. Lim. 1998- 2000.
22. Edwin Chen. Graduate Student (Ph.D.). Institute of Medical Science, University of Toronto. Co-supervisor with M. Hough, 2000- 2003.
23. Rama Grantab. Graduate Student (M.Sc.). Department of Laboratory Medicine and Pathobiology. University of Toronto. Co-supervisor with M. Hough. 2001-2002.
24. Jotesh S. Chug. Graduate Student (M.Sc.). Department of Laboratory Medicine and Pathobiology. University of Toronto. Co-supervisor with M. Hough. 2001-2002.
25. Ali Rouhani. Graduate Student (Ph.D.). Department of Laboratory Medicine and Pathobiology. University of Toronto. Co-supervisor with M. Hough. 2002-2003.
26. Baiwei Gong. Graduate Student (M.Sc.) Institute of Medical Sciences. University of Toronto. Co-supervisor with M. Hough. 2002-2003.

**N. Graduate Student Examining Committees**

1. Otto Sweatman-Sanchez, M.D. [E. deHarven, Supervisor]. M.Sc. (Pathology). Thesis defence; September 24, 1990, University of Toronto.
2. Sharon Elizabeth Bodrug, [R. Worton, Supervisor]. Ph.D. (Medical Genetics). Thesis defence, February 6, 1991, University of Toronto.

3. Dorothee Bienzle, DVM. [R. Jacobs, Supervisor]. M.Sc. (Pathology). Thesis defence, April 24th, 1992, University of Guelph.
4. Satyajit Battacharya, M.Sc. [J. Minta, Supervisor]. M.Sc. (Pathology). Thesis defence, January 28th, 1993, University of Toronto.
5. Lilly Noble, M.Sc. [I. Dubé and S. Kamel-Reid, Supervisors]. M.Sc. (Pathology). Thesis defence, November 30th, 1993, University of Toronto.
6. Peter Chu, M.Sc. [I. Dubé, Supervisor]. M.Sc. (Cellular & Molecular Pathology). Thesis defence, September 21, 1996, University of Toronto.
7. Jeff Hummel, M.Sc. [I. Dubé and S. Kamel-Reid, Supervisors]. M.Sc. (Medical Sciences). Thesis defence, September 25, 1995, University of Toronto.
8. Jessica Jolly, M.Sc. (M. Reis, Supervisor). M.Sc. (Laboratory Medicine & Pathobiology). Thesis defence, April 1, 1999, University of Toronto.
9. Carolyn Lutzko, Ph.D. [I. Dubé, Supervisor]. Ph.D. (Laboratory Medicine & Pathobiology). Thesis defence, April 9, 1999, University of Toronto.
10. Elizabeth Plowright, M.Sc. [K. Stewart and I. Dubé, Supervisors]. M.Sc. (Medical Sciences). Thesis defence, June 21, 1999, University of Toronto.
11. Ninos Yacoub, B.Sc. [I. Dubé and C. Catzavelos, Supervisors]. M.Sc. (Laboratory Medicine and Pathobiology). Thesis defence, November 26, 1999, University of Toronto.
12. Saul Mandelbaum, M.Sc. [A.K. Stewart, Supervisor]. M.Sc. (Medical Sciences). Thesis defence, February 18, 2000, University of Toronto.
13. Rosic-Kablar, M.D. [I. Dubé, Supervisor]. M.Sc. (Laboratory Medicine and Pathobiology). Thesis defence, November 1, 1999, University of Toronto.
14. Mary Anne Viani, (M.Sc.). [I. Dubé and M. Lim, Supervisors]. M.Sc. (Department of Laboratory Medicine & Pathobiology). Thesis defence, May 3, 2000, University of Toronto
15. Tarja Juopperi, DVM. [Thesis Supervisor]. M.Sc. (Laboratory Medicine and Pathobiology). Thesis defence, June 8, 2000, University of Toronto.

## O. Visiting Professors

1. Zhao Ying, Ph.D. Associate Professor, Department of Medical Genetics, Chinese Academy of Medical Sciences, Beijing, China. November 1988 - February 1989 and May 1989 - December 1989.
2. Shan-Gen Lu, M.D. Professor and Chief, Department of Pediatrics, Chinese Great Wall Hospital, Chinese PLA General Hospital, Military Post-graduate medical school, Beijing, China. December 1990-June, 1991.
3. Yevgeni Lifshits, M.D. Director of Pediatric Hematology, Hospital #14, Kiev, Ukraine. September, 1994.
4. Johan Richter, M.D., National Institute of Health, Maryland, U.S.A., May, 1996.
5. Cecilia Fahlman M.D., National Institute of Health, Maryland, U.S.A., May, 1996.
6. Christopher Baum, M.D. Heinrich-Pette Institut, Hamburg, Germany, August, 1996.